BioSig (BSGM) 10-K 14 Mar 16 2015 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Mar. 14, 2016	Jun. 30, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	BIOSIG TECHNOLOGIES, INC.
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		17,250,703
Entity Public Float			$ 14,284,005
Amendment Flag	false
Entity Central Index Key	1,530,766
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Smaller Reporting Company
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

BALANCE SHEETS

BALANCE SHEETS - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash	$ 953,234	$ 239,781
Prepaid expenses	31,308	75,537
Total current assets	984,542	315,318
Property and equipment, net	18,408	13,020
Other assets:
Deposits	27,612	25,000
Total assets	1,030,562	353,338
Current liabilities:
Accounts payable and accrued expenses, including $12,716 and $40,293 to related parties as of December 31, 2015 and 2014 respectively	223,546	554,026
Stock based payable	0	226,305
Dividends payable	340,291	445,069
Warrant liability	1,621,199	0
Derivative liability	285,157	0
Total current liabilities	2,470,193	1,225,400
Series C Preferred Stock, 1,471 and 2,711 shares issued and outstanding as of December 31, 2015 and 2014, respectively, liquidation preference of $1,471,000 and $2,711,000 as of December 31, 2015 and 2014, respectively	$ 1,471,000	$ 2,711,000
Commitments and contingencies
Stockholders' deficit
Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B and 4,200 shares of Series C Preferred Stock	$ 0	$ 0
Common stock, $0.001 par value, authorized 50,000,000 shares, 16,825,703 and 11,179,266 issued and outstanding as of December 31, 2015 and 2014, respectively	16,826	11,179
Additional paid in capital	29,314,399	19,186,163
Accumulated deficit	(32,241,856)	(22,780,404)
Total stockholders' deficit	(2,910,631)	(3,583,062)
Total liabilities and stockholders' deficit	$ 1,030,562	$ 353,338

BALANCE SHEETS (Parentheticals)

BALANCE SHEETS (Parentheticals) - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Accounts payable and accrued expenses, related parties (in Dollars)	$ 12,716	$ 40,293
Preferred stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	50,000,000	50,000,000
Common stock, shares issued	16,825,703	11,179,266
Common stock, shares outstanding	16,825,703	11,179,266
Series C Preferred Stock [Member]
Preferred stock, shares issued	1,471	2,711
Preferred stock, shares outstanding	1,471	2,711
Preferred stock, liquidation preference (in Dollars)	$ 1,471,000	$ 2,711,000
Preferred stock, shares authorized	4,200	4,200
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	184.4
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	177.5

STATEMENTS OF OPERATIONS

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Operating expenses:
Research and development	$ 1,238,548	$ 547,996
General and administrative	10,795,007	7,304,440
Depreciation	10,475	15,809
Total operating expenses	12,044,030	7,868,245
Loss from operations	(12,044,030)	(7,868,245)
Other income (expense):
Gain on change in fair value of derivatives	3,113,580	0
Interest income (expense)	(1,298)	(11,025)
Financing costs	(529,704)	(593,770)
Total other income (expense)	2,582,578	(604,795)
Loss before income taxes	(9,461,452)	(8,473,040)
Income taxes (benefit)	0	0
Net loss	(9,461,452)	(8,473,040)
Preferred stock dividend	(351,522)	(300,359)
NET LOSS AVAILABLE TO COMMON STOCKHOLDERS	$ (9,812,974)	$ (8,773,399)
Net loss per common share, basic and diluted (in Dollars per share)	$ (0.70)	$ (0.91)
Weighted average number of common shares outstanding, basic and diluted (in Shares)	14,103,055	9,650,275

STATEMENT OF STOCKHOLDERS' DEFI

STATEMENT OF STOCKHOLDERS' DEFICIT - USD ($)	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]Additional Paid-in Capital [Member]	Embedded Derivative Financial Instruments [Member]Series C Preferred Stock [Member]	Embedded Derivative Financial Instruments [Member]	Preferred Stock [Member]	Common Stock [Member]Cashless Exercise of Warrants [Member]	Common Stock [Member]Exercise of Options [Member]	Common Stock [Member]Exercise of Warrants for Cash [Member]Warrants at $3.67 [Member]	Common Stock [Member]Exercise of Warrants for Cash [Member]Warrants at $2.50 [Member]	Common Stock [Member]Series A Preferred Stock [Member]	Common Stock [Member]Series B Preferred Stock [Member]	Common Stock [Member]Series C Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]Cashless Exercise of Warrants [Member]Warrant [Member]	Additional Paid-in Capital [Member]Cashless Exercise of Warrants [Member]	Additional Paid-in Capital [Member]Exercise of Options [Member]	Additional Paid-in Capital [Member]Exercise of Warrants for Cash [Member]Warrants at $3.67 [Member]	Additional Paid-in Capital [Member]Exercise of Warrants for Cash [Member]Warrants at $2.50 [Member]	Additional Paid-in Capital [Member]Warrant [Member]	Additional Paid-in Capital [Member]Series A Preferred Stock [Member]	Additional Paid-in Capital [Member]Series B Preferred Stock [Member]	Additional Paid-in Capital [Member]Series C Preferred Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Cashless Exercise of Warrants [Member]Warrant [Member]	Cashless Exercise of Warrants [Member]	Exercise of Options [Member]	Exercise of Warrants for Cash [Member]Warrants at $3.67 [Member]	Exercise of Warrants for Cash [Member]Warrants at $2.50 [Member]	Exercise of Warrants for Cash [Member]	Warrant [Member]	Series A Preferred Stock [Member]	Series B Preferred Stock [Member]	Series C Preferred Stock [Member]	Total
Balance, December 31, 2013 at Dec. 31, 2013					$ 0								$ 8,412										$ 9,036,038	$ (14,007,005)											$ (4,962,555)
Balance, December 31, 2013 (in Shares) at Dec. 31, 2013					0								8,412,101
Sale of common stock													$ 956										1,968,454												$ 1,969,410
Sale of common stock (in Shares)													956,179																						956,179
Common stock issued for services													$ 654										1,634,346												$ 1,635,000
Common stock issued for services (in Shares)													654,000
Common stock issued in settlement of related party debt													$ 26										64,974												65,000
Common stock issued in settlement of related party debt (in Shares)													26,000
Common stock issued upon conversion of preferred stock and accrued dividends										$ 578	$ 494	$ 59								$ 1,062,753	$ 997,032	$ 88,841										$ 1,063,331	$ 997,526	$ 88,900
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)										577,901	493,818	59,267
Donated capital																							87,500												87,500
Equity warrants issued to placement agent for sale of common stock																							52,800												52,800
Fair value of vested options																							4,193,425												4,193,425
Preferred stock dividend																								(300,359)											(300,359)
Net loss																								(8,473,040)											(8,473,040)
Balance at Dec. 31, 2014					$ 0								$ 11,179										19,186,163	(22,780,404)											$ (3,583,062)
Balance (in Shares) at Dec. 31, 2014					0								11,179,266																						11,179,266
Sale of common stock													$ 2,645										4,757,153											2,146,302	$ 4,759,798
Sale of common stock (in Shares)													2,645,432																						2,645,432
Common stock issued for services													$ 1,453										3,340,299												$ 3,341,752
Common stock issued for services (in Shares)													1,452,500
Common stock issued upon conversion of preferred stock and accrued dividends						$ 100	$ 10	$ 4	$ 4			$ 1,431			$ (100)	$ 20,890	$ 14,977	$ 9,996				$ 2,144,870					$ 20,900	$ 14,981	$ 10,000					$ 2,146,302
Common stock issued upon conversion of preferred stock and accrued dividends (in Shares)						99,552	10,000	4,082	4,000			1,430,871														99,552				8,082
Fair value reclassification	$ 639,467	$ (1,242,590)	$ 639,467	$ (1,242,590)										$ 265,955					$ (4,097,444)						$ 265,955						$ (4,097,444)
Stock based compensation																							4,626,284												4,626,284
Preferred stock dividend																							(351,522)												(351,522)
Net loss																								(9,461,452)											(9,461,452)
Balance at Dec. 31, 2015					$ 0								$ 16,826										$ 29,314,399	$ (32,241,856)											$ (2,910,631)
Balance (in Shares) at Dec. 31, 2015					0								16,825,703																						16,825,703

STATEMENT OF STOCKHOLDERS' DEF6

STATEMENT OF STOCKHOLDERS' DEFICIT (Parentheticals)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
Warrants exercised (in Shares) | shares	164,184
Exercise of options at	$ 2.09
Warrants at $3.67 [Member]
Exercise of warrants at	3.67
Warrants at $2.50 [Member]
Exercise of warrants at	$ 2.50
Cashless Exercise of Warrants [Member]
Warrants exercised (in Shares) | shares	156,102
Exercise of Warrants for Cash [Member]
Exercise of warrants at	$ 3.09
Common Stock [Member] | Series C Preferred Stock [Member]
Conversion of preferred stock at	$ 1.50
Common Stock [Member] | Cashless Exercise of Warrants [Member]
Warrants exercised (in Shares) | shares	156,102
Common Stock [Member] | Exercise of Options [Member]
Exercise of options at	$ 2.09
Common Stock [Member] | Exercise of Warrants for Cash [Member] | Warrants at $3.67 [Member]
Exercise of warrants at	3.67
Common Stock [Member] | Exercise of Warrants for Cash [Member] | Warrants at $2.50 [Member]
Exercise of warrants at	$ 2.50

STATEMENTS OF CASH FLOWS

STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,461,452)	$ (8,473,040)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation	10,475	15,809
Amortization of debt discount	585,324	593,770
Change in derivative liabilities	(3,113,580)	0
Equity based compensation	7,968,036	5,743,425
Changes in operating assets and liabilities:
Prepaid expenses	44,229	8,715
Accounts payable	(333,494)	(110,844)
Stock based payable	(226,305)	226,305
Deferred rent payable	3,016	(1,212)
Net cash used in operating activities	(4,523,751)	(1,997,072)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(15,863)	(3,963)
Payment of long term deposit	(2,612)	0
Net cash used in investing activity	(18,475)	(3,963)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock	4,759,798	1,969,410
Proceeds from sale of Series C Preferred Stock	450,000	0
Proceeds from exercise of options	20,900	0
Proceeds from exercise of warrants	24,981	0
Net repayments of related party advances	0	(30,781)
Net cash provided by financing activities	5,255,679	1,938,629
Net increase (decrease) in cash and cash equivalents	713,453	(62,406)
Cash and cash equivalents, beginning of the period	239,781	302,187
Cash and cash equivalents, end of the period	953,234	239,781
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	1,298	11,025
Cash paid during the period for income taxes	0	0
Non cash investing and financing activities:
Related party donated capital	0	87,500
Stock Issued for Services [Member]
Non cash investing and financing activities:
Common stock issued	0	85,000
Stock Issued for Settlement of Related Party Note and Advances Payable [Member]
Non cash investing and financing activities:
Common stock issued	0	65,000
Series A Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	0	1,063,331
Series B Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	0	997,526
Series C Preferred Stock [Member]
Non cash investing and financing activities:
Common stock issued upon conversion preferred stock and accrued dividends	$ 2,146,302	$ 88,900

NOTE 1 - SUMMARY OF SIGNIFICANT

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES A summary of the significant accounting policies applied in the preparation of the accompanying financial statements follows. Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise. Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates. Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2015 and 2014, deposits in excess of FDIC limits were $703,234 and $-0-, respectively. Prepaid Expenses From time to time, the Company issues shares of its common stock for services to be performed. The fair value of the common stock is determined at the date of the contract for services and is amortized ratably over the term of the contract. As of December 31, 2015 and 2014, prepaid expenses relating to stock based payments were $-0- and $56,667, respectively. Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Long-Lived Assets The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell. Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value. Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2015 and 2014, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 8). Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,238,548 and $547,996 for the year ended December 31, 2015 and 2014, respectively. Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial. Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2015 2014 Series C convertible preferred stock 980,667 1,807,333 Options to purchase common stock 7,780,190 5,990,190 Warrants to purchase common stock 7,078,685 5,113,990 Totals 15,839,542 12,911,513 Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2015, there were outstanding stock options to purchase 7,780,190 shares of common stock, 5,613,501 shares of which were vested. As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested. Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units , which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 2 - GOING CONCERN AND MANA

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS	12 Months Ended
	Dec. 31, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	NOTE 2 – GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying financial statements during the years ended December 31, 2015 and 2014, the Company incurred net losses attributable to common stockholders of $9,812,974 and $8,773,399, respectively and used $4,523,751 in cash for operating activities for the year ended December 31, 2015. These factors among others raise substantial doubt about the Company’s ability to continue as a going concern for a reasonable period of time. The Company's existence is dependent upon management's ability to develop profitable operations. The Company completed financing subsequent to the date of these financial statements (See Note 14). However additional capital will be needed to continue developing its products and services and there can be no assurance that the Company's efforts will be successful. There is no assurance that can be given that management's actions will result in profitable operations or the resolution of its liquidity problems. The accompanying statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

NOTE 3 - RELATED PARTY TRANSACT

NOTE 3 - RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2015
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	NOTE 3 – RELATED PARTY TRANSACTIONS The Company’s President and shareholders have advanced funds to the Company for working capital purposes since the Company’s inception in February 2009. No formal repayment terms or arrangements exist and the Company is not accruing interest on these advances. As of December 31, 2015 and 2014, all advances had been repaid. Accrued expenses due related parties as of December 31, 2015 and 2014 was $12,716 and $40,293, respectively. On August 1, 2012, we entered into a consulting agreement with Asher Holzer, Ph.D., then a member of our board of directors. Pursuant to the consulting agreement, Dr. Holzer was to serve as our chief scientific officer and assist in the development of our technology and our PURE EP System, in exchange for monthly payments of $10,000. We paid Dr. Holzer an initial payment of $7,500 pursuant to the consulting agreement. In the first quarter of 2014, we agreed to an oral amendment to our consulting agreement with Dr. Holzer, which resulted in Dr. Holzer agreeing to receive (i) a payment of $65,000, to be paid by us upon our closing of a capital raising transaction that results in proceeds to us of at least $5 million, and (ii) a future option grant to purchase 125,000 shares of our common stock, in exchange for acknowledging that no other payments are due by us to Dr. Holzer pursuant to the consulting agreement. On September 1, 2014, we entered into a letter agreement and release with Dr. Holzer, pursuant to which Dr. Holzer agreed to cancel, extinguish and terminate all amounts due or owed by us for services performed by Dr. Holzer pursuant to that certain consulting agreement, dated as of August 1, 2012, as amended. In connection with the cancellation of all payment obligations and in exchange for Dr. Holzer waiving and releasing us from all possible claims related to such obligations under the consulting agreement, Dr. Holzer received 26,000 shares of our common stock. Dr. Holzer also agreed to provide us with one additional year of consulting services in exchange for 34,000 shares of common stock. On January 31, 2014, as part of a private placement transaction of our common stock and warrants, On March 5, 2014, Mr. Steinhouse made an advance of funds to us in the aggregate amount of $10,000, which was repaid in full on April 3, 2014. The advance was interest-free and not made on condition of any specific terms. On September 12, 2014, Sterne Agee & Leach Inc. C/F Jonathan Steinhouse R/O IRA, as part of a private placement transaction of our common stock and warrants, purchased an aggregate of 4,000 shares of common stock and a warrant to purchase 2,000 shares of common stock for an aggregate purchase price of $10,000. During 2014, one of the Company’s board of directors forgave an outstanding obligation of $87,500 for services. Accordingly, the Company reclassified the liability to equity as donated capital. During 2014, the Company issued 34,000 shares of its common stock for future services to a board member totaling $85,000 ($2.50 per share), unrelated to his services as a board member. The fair value of the services is amortized over the service period. As of December 31, 2014, the unamortized portion of $56,667 is included in prepaid expenses in the accompanying balance sheet. During 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 debt to a board of directors’ member ($2.50 per share). On January 31, 2014, as part of a private placement transaction of our common stock and warrants, a related party purchased an aggregate of 24,490 shares of common stock and a warrant to purchase 12,246 shares of common stock for an aggregate purchase price of $60,000. On March 23, 2015, we issued Mr. Londoner an aggregate of 169,334 shares of common stock in exchange for 200 shares of our Series C 9% Convertible Preferred Stock and accrued dividends. On April 30, 2015, Mr. Chaussy was granted 150,000 shares of common stock at a cost basis of $2.90 per share for his 2013-2015 performance. One half of the shares vested immediately; the second half vests on January 1, 2016. On October 19, 2015, we entered into a consulting agreement with Dr. Holzer. Pursuant to the consulting agreement, Dr. Holzer is to provide certain consulting services in connection with the development and commercialization of our products, in exchange for a stock option for the purchase of 100,000 shares of common stock, vesting 50% on the first anniversary of the grant date and the remaining 50% on the second anniversary of the grant date, at an exercise price of $1.56 per share and termination date of October 19, 2025. On October 23, 2015, as part of a private placement transaction of our common stock and warrants, a related party purchased an aggregate of 66,667 shares of common stock and a warrant to purchase 33,334 shares of common stock for an aggregate purchase price of $100,000. On November 18, 2015, as part of a private placement transaction of our common stock and warrants, Donald E. Foley purchased an aggregate of 200,000 shares of common stock and a warrant to purchase 100,000 shares of common stock for an aggregate purchase price of $300,000. The Company has informal compensation and consulting agreements with employees and outside contractors, certain of whom are also Company stockholders. The Agreements are generally month to month. As of December 31, 2015 and 2014, total due under these agreements and related expenses were $-0- and $11,250, respectively.

NOTE 4 - PROPERTY AND EQUIPMENT

NOTE 4 - PROPERTY AND EQUIPMENT	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	NOTE 4 – PROPERTY AND EQUIPMENT Property and equipment as of December 31, 2015 and 2014 is summarized as follows: 2015 2014 Computer equipment $ 68,449 $ 54,900 Furniture and fixtures 10,117 7,803 Subtotal 78,566 62,703 Less accumulated depreciation (60,158 ) (49,683 ) Property and equipment, net $ 18,408 $ 13,020 Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings. Depreciation expense was $10,475 and $15,809 at December 31, 2015 and 2014, respectively.

NOTE 5 - ACCOUNTS PAYABLE AND A

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	NOTE 5 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES Accounts payable and accrued expenses at December 31, 2015 and 2014 consist of the following: 2015 2014 Accrued accounting and legal $ 112,723 $ 190,767 Accrued reimbursements 13,613 26,792 Accrued consulting 15,200 16,334 Accrued research and development expenses 34,179 93,407 Accrued credit card obligations - 13,278 Accrued payroll - 62,068 Accrued liquidated damages - 55,620 Accrued office and other 31,482 29,093 Deferred rent 3,016 - Accrued settlement related to arbitration 13,333 66,667 $ 223,546 $ 554,026

NOTE 6 - REDEEMABLE PREFERRED S

NOTE 6 - REDEEMABLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2015
Redeemable Preferred Stock [Abstract]
Redeemable Preferred Stock [Text Block]	NOTE 6 – REDEEMABLE PREFERRED STOCK Series A Preferred Stock In May 2011, the Board of Directors authorized the issuance of up to 200 shares of Series A Preferred Stock (the “Series A preferred stock”). The Series A preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on August 31, 2011 and are cumulative. The holders of Series A preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series A preferred stock, the Company cannot, (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation. The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid. The Series A preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $1.84 per share. On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 577,901 shares of its common stock in exchange for all the outstanding Series A preferred stock and accrued dividends of $141,331. Series B Preferred Stock On November 28, 2011, the Board of Directors authorized the issuance of up to 600 shares of Series B Preferred Stock (the “Series B preferred stock”). The Series B preferred stock is entitled to preference over holders of junior stock upon liquidation in the amount of $5,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 5% per annum of the Stated Value of $5,000 per share, payable quarterly beginning on December 31, 2011 and are cumulative. The holders of Series B preferred stock have no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series B preferred stock, the Company cannot (a) alter or change adversely the powers, preferences or rights given to the Series A preferred stock or alter or amend the Certificate of Designation. The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid. The Series B preferred stock is convertible (as amended), automatically, inclusive of any accrued and unpaid dividends, immediately into the Company’s common stock upon the Company becoming subject to the reporting requirements under Section 13 or 15(d) of the Securities and Exchange Act of 1934, as amended at conversion price of $2.02 per share. On June 23, 2014, upon the effectiveness of the Company’s registration statement, the Company issued an aggregate of 493,818 shares of its common stock in exchange for all the outstanding Series B preferred stock and accrued dividends of $110,026.

NOTE 7 - SERIES C 9% CONVERTIBL

NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Preferred Stock [Text Block]	NOTE 7 – SERIES C 9% CONVERTIBLE PREFERRED STOCK On January 9, 2013, the Board of Directors authorized the issuance of up to 4,200 shares of 9% Series C Convertible Preferred Stock (the “Series C Preferred Stock”). The Series C Preferred Stock is entitled to preference over holders of junior stock upon liquidation in the amount of $1,000 plus any accrued and unpaid dividends; entitled to dividends as a preference to holders of junior stock at a rate of 9% per annum of the stated value of $1,000 per share, payable quarterly beginning on September 30, 2013 and are cumulative. The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder. The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, which holders must include Alpha Capital Anstalt, so long as Alpha Capital Anstalt holds not less than $100,000 of Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including: ● incur additional indebtedness; ● permit liens on assets; ● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; ● pay cash dividends to our stockholders; and ● engage in transactions with affiliates. Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection. In the event that (i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered, (ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered, (iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, (v) we are party to a change of control transaction, (vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days, The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%. The Company determined that certain of the defined triggering events were outside the Company’s control and therefore classified the Series C Preferred Stock outside of equity. In connection with the sale of the Series C preferred stock, the Company issued an aggregate of 1,330,627 warrants to purchase the Company’s common stock at $2.61 per share expiring five years from the initial exercise date. The warrants contain full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $2.61 per share as well as other customary anti-dilution protection. The warrants are exercisable for cash; or if at any time after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”. As a result of an amendment to the conversion price of our Series C Preferred Stock, the full-ratchet anti-dilution protection provision of the warrants decreased the exercise price of the warrants from $2.61 per share to $1.50 per share and increased the aggregate number of shares issuable under the warrants to 2,315,301. In accordance with ASC 470-20, at issuance, the Company recognized an embedded beneficial conversion feature present in the Series C Preferred Stock when it was issued. The Company allocated the net proceeds between the intrinsic value of the conversion option ($1,303,671) and the warrants ($1,064,739) to additional paid-in capital. The aggregate debt discount, comprised of the relative intrinsic value of the conversion option ($1,303,671), the relative fair value of the warrants ($1,064,739), and the issuance costs ($412,590), for a total of $2,781,000, is amortized over an estimated one year as interest expense. During the month of February 2013, the holders of previously issued convertible bridge notes converted into 600 shares of the Company’s Series C Preferred Stock. During the months of February, March, May, and July 2013, the Company sold an aggregate of 2,181 shares of the Company’s Series C Preferred Stock for net proceeds of $1,814,910. At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related issued warrants did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation is not required. There was no established market for the Company’s common stock. As described in Note 8, as of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively, from equity to liabilities. At March 31, 2015, the Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: contractual terms of 2.78 to 3.50 years, a risk free interest rate of 0.56% to 0.89%, a dividend yield of 0%, and volatility of 141.00%. During December 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. During January 2015, the Company issued an aggregate of 42,334 shares of its common stock in exchange for 50 shares of the Company’s Series C Preferred Stock and accrued dividends. During March 2015, the Company issued an aggregate of 169,334 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In April 2015, the Company issued an aggregate of 152,401 shares of its common stock in exchange for 180 shares of the Company’s Series C Preferred Stock and accrued dividends. On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000. In connection with the sale, the Company issued 374,641 warrants to purchase the Company’s common stock at an exercise price of $1.50 per share for five years with certain reset provisions as described above. The Company determined the initial fair values of the embedded beneficial conversion feature of the Series C Preferred Stock and the reset provisions of the related issued warrants $506,348 and $334,784, respectively, using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.25%, a dividend yield of 0%, and volatility of 140.00%. The determined fair values were recorded as liabilities and a charge to current period operations. In May 2015, the Company issued an aggregate of 273,473 shares of its common stock in exchange for 323 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2015, the Company issued an aggregate of 296,333 shares of its common stock in exchange for 350 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2015, the Company issued an aggregate of 169,333 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In October 2015, the Company issued an aggregate of 143,935 shares of its common stock in exchange for 170 shares of the Company’s Series C Preferred Stock and accrued dividends. In November 2015, the Company issued an aggregate of 99,061 shares of its common stock in exchange for 117 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2015, the Company issued an aggregate of 84,667 shares of its common stock in exchange for 100 shares of the Company’s Series C Preferred Stock and accrued dividends. For the year ended December 31, 2015, at the time of conversions, the Company reclassified the fair value of the embedded beneficial conversion feature of the Series C Preferred Stock of $639,467 from liability to equity. The fair values were determined using a Multinomial Lattice pricing model and the following assumptions: estimated contractual terms of 2.00 years, a risk free interest rate of 0.23% to 0.27%, a dividend yield of 0%, and volatility from 139% to 147.00%. Series C Preferred Stock issued and outstanding totaled 1,471 and 2,711 as of December 31, 2015 and 2014, respectively. As of December 31, 2015 and 2014, the Company has accrued $340,291 and $445,069 dividends payable on the Series C Preferred Stock. Registration Rights Agreement In connection with the Company’s private placement of Series C Preferred Stock and warrants, the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed a registration statement on July 22, 2013, which was originally declared effective on June 23, 2014. As a result, the Company accrued $55,620 as interest expense for liquidating damages due under the registration rights agreement as of December 31, 2014. At December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations.

NOTE 8 - WARRANT AND DERIVATIVE

NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block [Abstract]
Derivatives and Fair Value [Text Block]	NOTE 8 – WARRANT AND DERIVATIVE LIABILITIES At the time of issuance and until March 31, 2015, the Company determined that the anti-dilutive provisions embedded in the Series C Preferred Stock and related warrants (see Note 7) did not meet the defined criteria of a derivative in such that the net settlement requirement of delivery of common shares does not meet the “readily convertible to cash” as described in Accounting Standards Codification 815 and therefore bifurcation was not required. There was no established market for the Company’s common stock. As of March 31, 2015, the Company determined a market had been established for the Company’s common stock and accordingly, reclassified from equity to liability treatment the fair value of the embedded reset provisions of the Series C Preferred Stock and warrants of $1,242,590 and $4,097,444, respectively. The Company valued the reset provisions of the Series C Preferred Stock and warrants in accordance with ASC 470-20 using the Multinomial Lattice pricing model and the following assumptions: estimated contractual terms, a risk free interest rate of 0.56% to 0.89, a dividend yield of 0%, and volatility of 141.00%. At December 31, 2015, the Company marked to market the fair value of the reset provisions of the Series C Preferred Stock and warrants and determined fair values of $285,157 and $1,621,199, respectively. The Company recorded a gain from change in fair value of derivatives of $3,113,580 for the year ended December 31, 2015, respectively. The fair values of the embedded derivatives were determined using the Multinomial Lattice pricing model and the following assumptions: estimated contractual term of 2.00 years, a risk free interest rate of 1.01%, a dividend yield of 0%, and volatility of 147.00%.

NOTE 9 - STOCKHOLDER EQUITY

NOTE 9 - STOCKHOLDER EQUITY	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	NOTE 9 – STOCKHOLDER EQUITY There was not a viable market for the Company’s common stock to determine its fair value until October 29, 2014; therefore, prior to October 29, 2014, management was required to estimate the fair value to be utilized in the determining stock based compensation costs. In estimating the fair value, management considered recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management’s estimates. Preferred stock The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of December 31, 2015 and 2014, the Company has designated and issued 200 and 184.4 shares of Series A preferred stock, respectively, designated and issued 600 and 177.5 shares of Series B preferred stock, respectively. See Note 6. As of December 31, 2015 and 2014, the Company designated and issued 4,200 and 2,781 shares of Series C 9% convertible preferred stock, respectively. See Note 7. On June 23, 2014, the Company issued an aggregate of 577,901 and 493,818 shares of its common stock in exchange of all the issued and outstanding Series A and Series B preferred stock. During December 2014, the Company issued an aggregate of 59,267 shares of its commons stock in exchange for 70 shares of the Company’s Series C 9% Convertible Preferred Stock and accrued dividends. During January 2015, the Company issued an aggregate of 42,334 shares of its common stock in exchange for 50 shares of the Company’s Series C Preferred Stock and accrued dividends. During March 2015, the Company issued an aggregate of 169,334 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In April 2015, the Company issued an aggregate of 152,401 shares of its common stock in exchange for 180 shares of the Company’s Series C Preferred Stock and accrued dividends. On May 11, 2015, the Company sold an aggregate of 450 shares of its Series C Preferred Stock for net proceeds of $450,000. In connection with the sale, the Company issued 374,641 warrants to purchase the Company’s common stock at an exercise price of $1.50 per share for five years. In May 2015, the Company issued an aggregate of 273,473 shares of its common stock in exchange for 323 shares of the Company’s Series C Preferred Stock and accrued dividends. In June 2015, the Company issued an aggregate of 296,333 shares of its common stock in exchange for 350 shares of the Company’s Series C Preferred Stock and accrued dividends. In July 2015, the Company issued an aggregate of 169,333 shares of its common stock in exchange for 200 shares of the Company’s Series C Preferred Stock and accrued dividends. In October 2015, the Company issued an aggregate of 143,935 shares of its common stock in exchange for 170 shares of the Company’s Series C Preferred Stock and accrued dividends. In November 2015, the Company issued an aggregate of 99,061 shares of its common stock in exchange for 117 shares of the Company’s Series C Preferred Stock and accrued dividends. In December 2015, the Company issued an aggregate of 84,667 shares of its common stock in exchange for 100 shares of the Company’s Series C Preferred Stock and accrued dividends. Cumulatively from January 1, 2015 to December 31, 2015, the Company exchanged 1,690 shares of the Company’s Series C Preferred Stock and dividends with a recorded value of $2,146,302 for 1,430,871 shares of common stock. As of December 31, 2015 and 2014, the Company has 1,471 and 2,711 Series C Preferred Stock issued and outstanding. Common stock The Company is authorized to issue 50,000,000 shares of $0.001 par value common stock. As of December 31, 2015 and 2014, the Company had 16,825,703 and 11,179,266 shares issued and outstanding, respectively. During the year ended December 31, 2014, the Company issued 654,000 shares of its common stock (net of shares exchanged) under the terms of its 2012 Equity Plan for services rendered totaling $1,635,000 ($2.50 per share). During the year ended December 31, 2014, the Company issued 26,000 shares of its common stock in settlement of $65,000 related party debt ($2.50 per share). During the year ended December 31, 2014, the Company entered into a securities purchase agreement with investors pursuant to which the Company issued 956,179 shares of common stock and five-year warrants for aggregate net proceeds of $1,969,410. During the year ended December 31, 2015, the Company issued an aggregate of 1,452,500 shares of common stock under the terms of its 2012 Equity Plan for services rendered totaling $3,341,752 ($2.30 average per share). During the year ended December 31, 2015, the Company issued 10,000 shares of common stock in exchange for options exercised at $2.09 per share. During the year ended December 31, 2015, the Company issued an aggregate of 8,082 shares of common stock in exchange for warrants exercised at an average price of $3.09 per share. During the year ended December 31, 2015, the Company issued 99,552 shares of common stock in exchange for 156,102 warrants exercised on a cashless basis. During the year ended December 31, 2015, the Company entered into securities purchase agreements with investors pursuant to which the Company issued 2,645,432 shares of common stock and warrants for aggregate proceeds of $4,759,798, net of $608,356 in expenses. In connection with the securities purchase agreements described above, the Company entered into registration rights agreements with the purchasers in such private placements pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issued to the investors participating in such private placements and the common stock issuable upon exercise of the related warrants issued such investors. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the shares of common stock issued pursuant to the private placement and issuable upon the exercise of the warrants within 45 days of the termination date of such private placement and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and within 180 calendar days of the initial filing date of the registration statement in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments. If (i) the registration statement is not filed within 45 days of the applicable termination date, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within 30 calendar days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission within 180 calendar days of the initial filing date of the registration statement in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 10 consecutive calendar days or more than an aggregate of 15 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 1.0% of the aggregate purchase price paid by such purchasers per month of delinquency, provided, however, that the Company will not be required to make any payments any of the foregoing events occurred at such time that all securities registered or to be registered in the registration statement are eligible for resale pursuant to Rule 144 (without volume restrictions or current public information requirements) promulgated by the Securities and Exchange Commission pursuant to the Securities Act of 1933, as amended and provided, further, that the Company will not be required to make any liquidated damage payments with respect to any securities registered or to be registered in the registration statement that the Company is unable to register due to limits imposed by the Securities and Exchange Commission’s interpretation of Rule 415 under the Securities Act of 1933, as amended. Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreements dated December 31, 2013, April 4, 2014 and August 15, 2014 shall be 3% of the aggregate purchase price paid by the purchasers, (ii) the maximum aggregate liquidated damages due under the registration rights agreement dated December 19, 2014 shall be 6% of the aggregate purchase price paid by the purchasers and (iii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount. Pursuant to the registration rights agreements, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events. The Company filed a registration statement on May 20, 2015, which was declared effective on June 12, 2015 to satisfy the requirements under the registration rights agreements with the purchasers of its common stock and warrants prior to September 30, 2015. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units, which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement Stock based payable The Company is obligated to issue shares of its common stock to board members and consultants for past and future services. The estimated liability as of December 31, 2015 and 2014 of $-0- and $226,305 was determined based on services rendered for past services as of December 31, 2015 and 2014, respectively.

NOTE 10 - OPTIONS AND WARRANTS

NOTE 10 - OPTIONS AND WARRANTS	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Shareholders' Equity and Share-based Payments [Text Block]	NOTE 10 – OPTIONS AND WARRANTS There was not a viable market for the Company’s common stock to determine its fair value until October 29, 2014; therefore, prior to October 29, 2014, management was required to estimate the fair value to be utilized in the determining stock based compensation costs. In estimating the fair value, management considered recent sales of its common stock to independent qualified investors, placement agents’ assessments of the underlying common shares relating to our sale of preferred stock and validation by independent fair value experts. Considerable management judgment is necessary to estimate the fair value. Accordingly, actual results could vary significantly from management’s estimates. Options On October 19, 2012, the Company’s Board of Directors approved the 2012 Equity Incentive Plan (“the “2012 Plan) and terminated the Long-Term Incentive Plan (the “2011 Plan”). The Plan provides for the issuance of options to purchase up to 11,686,123,(as amended) shares of the Company’s common stock to officers, directors, employees and consultants of the Company (as amended). Under the terms of the Plan the Company may issue Incentive Stock Options as defined by the Internal Revenue Code to employees of the Company only and nonstatutory options. The Board of Directors of the Company determines the exercise price, vesting and expiration period of the grants under the Plan. However, the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder. The fair value of the common stock is determined based on quoted market price or in absence of such quoted market price, by the Board of Directors in good faith. Additionally, the vesting period of the grants under the Plan will be determined by the Committee, in its sole discretion, and expiration period not more than ten years. The Company reserved 1,250,000 shares of its common stock for future issuance under the terms of the Plan. During the year ended December 31, 2014, the Company granted an aggregate of 3,478,498 options and 654,000 stock grants (net of shares exchanged) to officers, directors and key consultants. During the year ended December 31, 2015, the Company granted an aggregate of 1,800,000 options and 1,452,500 stock grants (net of shares exchanged) to officers, directors and key consultants. The following table presents information related to stock options at December 31, 2015: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 1,544,642 6.3 910,142 2.01-3.00 5,935,548 6.3 4,403,359 3.01-4.00 300,000 9.3 300,000 7,780,190 6.4 5,613,501 A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2015 and 2014 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2014 2,990,977 $ 2.05 6.02 $ - Grants 3,478,498 2.39 8.10 $ - Exercised - - - - Canceled (479,285 ) $ (2.00 ) - Outstanding at December 31, 2014 5,990,190 $ 2.25 6.7 $ 3,267,692 Grants 1,800,000 2.70 8.9 $ - Exercised (10,000 ) 2.09 Canceled - Outstanding at December 31, 2015 7,780,190 $ 2.30 6.4 $ - Exercisable at December 31, 2015 5,613,501 $ 2.35 5.8 $ - The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on options with an exercise price less than the Company’s stock price of $1.30 as of December 31, 2015, which would have been received by the option holders had those option holders exercised their options as of that date. Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities until sufficient data exists to estimate the volatility using the Company’s own historical stock prices. Management determined this assumption to be a more accurate indicator of value. The Company accounts for the expected life of options based on the contractual life of options for non-employees. For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options. The fair value of stock-based payment awards during the years ended December 31, 2015 and 2014 was estimated using the Black-Scholes pricing model. In addition, the Company is required to estimate the expected forfeiture rate and only recognize expense for those shares expected to vest. In estimating the Company’s forfeiture rate, the Company analyzed its historical forfeiture rate, the remaining lives of unvested options, and the number of vested options as a percentage of total options outstanding. During the year ended December 31, 2014, the Company granted an aggregate of 3,478,498 options to purchase the Company’s common stock in connection with the services rendered at exercise prices from $2.21 to $2.50 per share for a term of seven years. Vesting is as follows: 1,491,983 Exercisable immediately 125,000 Per quarter, over one year 1,126,552 Per quarter, over two years 734,963 Performance contingent 3,478,498 The fair value of the granted options for the year ended December 31, 2014 was determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: -0- % Volatility 119.43% to 129.88 % Risk free rate: 0.48% to 2.53 % Expected life: 7 to 10 years Estimated fair value of the Company’s common stock $ $2.21 to $2.50 Estimated forfeiture rate 0 % During the year ended December 31, 2015, the Company granted an aggregate of 1,800,000 options to purchase the Company’s common stock in connection with the services rendered at exercise prices from $1.56 to $3.99 per share for a term of seven years. Vesting is as follows: 737,500 Exercisable immediately 155,000 Per quarter, over one year 250,000 Per quarter, over three years 225,000 One year anniversary 300,000 1/12 per month beginning first month anniversary 100,000 50% one year anniversary, 50% two year anniversary 32,500 Performance contingent 1,800,000 The fair value of the granted options for the year ended December 31, 2015 was determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: -0- % Volatility 118.56% to 130.30 % Risk free rate: 1.19% to 2.37 % Expected life: 7 to 10 years Estimated fair value of the Company’s common stock $ 1.42 to $3.99 Estimated forfeiture rate 0 % On April 22, 2015, the Company issued 10,000 shares of common stock in exchange for options exercised at $2.09 per share. The fair value of all options vesting during the year ended December 31, 2015 and 2014 of $4,471,603 and $4,193,425, respectively, was charged to current period operations. Unrecognized compensation expense of $1,782,575 and $3,778,589 at December 31, 2015 and 2014, respectively, will be expensed in future periods. Restricted Stock The following table summarizes the restricted stock activity for the year ended December 31, 2015: Restricted shares issued as of January 1, 2015 - Granted 175,000 Total restricted shares issued as of December 31, 2015 175,000 Vested restricted shares as of December 31, 2015 (75,000 ) Unvested restricted shares as of December 31, 2015 100,000 Stock based compensation expense related to restricted stock grants was $338,614 and $-0- for the year ended December 31, 2015 and 2014, respectively. As of December 31, 2015, the stock-based compensation relating to restricted stock of $53,386 remains unamortized. Warrants The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2015: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 3,991,391 February 2018 to December 2018 $ 1.84 35,076 January 2020 $ 1.95 654,674 October 2018 to December 2018 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 7,078,685 On January 31, 2014, the Company issued an aggregate of 64,626 warrants to purchase the Company’s common stock at $3.67 per share for five years in connection with the sale of the Company’s common stock. In February 2014, as described in the terms of the warrants issued in connection with the sale of the Series C preferred stock, the Company reset 2,138,800 previously issued warrants from a exercise price of $2.61 per share to $1.50. In addition, the Company was required to increase the number of issued warrants to an aggregate total of 3,721,518 warrants. In April 2014, the Company issued an aggregate of 137,856 warrants to purchase the Company’s common stock at $3.75 per share for five years in connection with the sale of the Company’s common stock. In August 2014, the Company issued an aggregate of 135,120 warrants to purchase the Company’s common stock at $2.75 per share for five years in connection with the sale of the Company’s common stock. In September 2014, the Company issued an aggregate of 93,600 warrants to purchase the Company’s common stock at $2.75 per share for five years in connection with the sale of the Company’s common stock. In December 2014, the Company issued an aggregate of 358,470 warrants to purchase the Company’s common stock in connection with the sale of the Company’s common stock. Of the aggregate issued, 204,840 warrants are exercisable at $2.50 expiring six months from the date of issuance and 153,630 warrants exercisable at $3.75 per share expiring March 31, 2020. On January 23, 2015, the Company issued an aggregate of 428,400 and 321,300 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On February 10, 2015, the Company issued an aggregate of 337,000 and 252,750 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On February 27, 2015, the Company issued an aggregate of 223,000 and 167,250 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On March 31, 2015, the Company issued an aggregate of 410,360 and 307,770 warrants to purchase the Company’s common stock at $2.50 and $3.75 per share, respectively, expiring on July 31, 2015 and March 31, 2020, respectively, in connection with the sale of the Company’s common stock. On April 15, 2015, the Company issued 99,552 shares of common stock in exchange for 156,102 warrants exercised on a cashless basis. On May 5, 2015, the Company issued 4,082 shares of common stock in exchange for 4,082 warrants exercised at $3.67 per share. On May 8, 2015, the Company issued 4,000 shares of common stock in exchange for 4,000 warrants exercised at $2.50 per share. On May 11, 2015, the Company issued an aggregate of 374,641 warrants to purchase the Company’s common stock at $1.50 per share expiring on May 11, 2020 in connection with the sale of the Company’s Series C Preferred stock. On August 17, 2015, the Company issued 100,000 and 100,000 warrants to purchase the Company’s common stock at $2.00 and 2.50 per share, respectively, expiring on August 17, 2018 in connection with services provided. Both warrants vest at 1/12 per month over one year. The fair value of the vested portion of the issued warrants of $104,505 was charged to current period operations and was determined using the Black-Scholes option model with a volatility figure derived from an index of historical stock prices of comparable entities of 118.80% to 118.88%, risk free rate of 0.92% to 1.31%, dividend yield of -0- and fair value of the Company’s common stock of $1,30 to $1.40. As of December 31, 2015, unrecognized compensation expense was $46,993. On October 23, 2015, the Company issued an aggregate of 108,336 warrants to purchase the Company’s common stock at $1.95, expiring on October 23, 2018, in connection with the sale of the Company’s common stock. In addition, the Company issued 11,334 warrants to purchase the Company’s common stock at $1.50, expiring October 23, 2018 for placement agent services. On October 29, 2015, the Company issued an aggregate of 43,334 warrants to purchase the Company’s common stock at $1.95, expiring on October 29, 2018, in connection with the sale of the Company’s common stock. In addition, the Company issued 6,134 warrants to purchase the Company’s common stock at $1.50, expiring October 29, 2018 for placement agent services. On November 18, 2015, the Company issued an aggregate of 188,335 warrants to purchase the Company’s common stock at $1.95, expiring on November 18, 2018, in connection with the sale of the Company’s common stock. In addition, the Company issued 25,200 warrants to purchase the Company’s common stock at $1.50, expiring November 18, 2018 for placement agent services. On December 18, 2015, the Company issued an aggregate of 116,668 warrants to purchase the Company’s common stock at $1.95, expiring on December 18, 2018, in connection with the sale of the Company’s common stock. In addition, the Company issued 20,000 warrants to purchase the Company’s common stock at $1.50, expiring December 18, 2018 for placement agent services. On December 22, 2015, the Company issued an aggregate of 166,667 warrants to purchase the Company’s common stock at $1.95, expiring on December 22, 2018, in connection with the sale of the Company’s common stock. In addition, the Company issued 20,000 warrants to purchase the Company’s common stock at $1.50, expiring December 22, 2018 for placement agent services. A summary of the warrant activity for the years ended December 31, 2015 and 2014 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2014 2,717,258 $ 2.28 6.02 - Grants 2,396,732 $ 4.64 2.05 - Exercised - - - - Canceled - - - - Outstanding at December 31, 2014 5,113,990 $ 1.71 3.6 $ 6,041,436 Grants 3,728,479 2.62 2.3 - Exercised (164,184 ) 1.58 Canceled (1,599,600 ) $ 2.50 Outstanding at December 31, 2015 7,078,685 $ 2.02 3.0 $ 497,933 Vested and expected to vest at December 31, 2015 7,078,685 $ 2.02 3.0 $ 497,933 Exercisable at December 31, 2015 6,945,353 $ 2.01 3.0 $ 497,933 The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the Company’s stock price of $1.30 as of December 31, 2015, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

NOTE 11 - FAIR VALUE MEASUREMEN

NOTE 11 - FAIR VALUE MEASUREMENT	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	NOTE 11 – FAIR VALUE MEASUREMENT The Company adopted the provisions of Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”). ASC 825-10 defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions, and risk of nonperformance. ASC 825-10 establishes a fair value hierarchy that requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 825-10 establishes three levels of inputs that may be used to measure fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities; quoted prices in markets with insufficient volume or infrequent transactions (less active markets); or model-derived valuations in which all significant inputs are observable or can be derived principally from or corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs to the valuation methodology that are significant to the measurement of fair value of assets or liabilities. All items required to be recorded or measured on a recurring basis are based upon level 3 inputs. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement is disclosed and is determined based on the lowest level input that is significant to the fair value measurement. Upon adoption of ASC 825-10, there was no cumulative effect adjustment to beginning retained earnings and no impact on the financial statements. The carrying value of the Company’s cash and cash equivalents, accounts payable and other current assets and liabilities approximate fair value because of their short-term maturity. As of December 31, 2015 and 2014, the Company did not have any items that would be classified as level 1 or 2 disclosures. The Company recognizes its derivative and warrant liabilities as level 3 and values its derivatives using the methods discussed in Note 8. While the Company believes that its valuation methods are appropriate and consistent with other market participants, it recognizes that the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date. The primary assumptions that would significantly affect the fair values using the methods discussed in Note 5 are that of volatility and market price of the underlying common stock of the Company. As of December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. The derivative and warrant liability as of December 31, 2015, in the amount of $285,157 and $1,621,199, respectively, has a level 3 classification. The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2015: Warrant Liability Derivative Balance, December 31, 2014 (and prior) $ - $ - Total (gains) losses Initial fair value of derivative at March 31, 2015, reclassified from equity - 1,242,590 Initial fair value of warrant liability at March 31, 2015, reclassified from equity 4,097,444 - Initial fair value of derivative at date of issuance of Series C Preferred Stock - 250,540 Initial fair value of warrant liability at the date of issuance 334,784 - Transfers out due to conversion of Series C Preferred Stock - (639,467 ) Transfers out due to exercise of warrants (265,955 ) - Mark to market to December 31, 2015 (2,545,074 ) (568,506 ) Balance, December 31, 2015 $ 1,621,199 $ 285,157 Gain on change in warrant and derivative liabilities for the year ended December 31, 2015 $ 2,545,074 $ 568,506 Fluctuations in the Company’s stock price are a primary driver for the changes in the derivative valuations during each reporting period. As the stock price decreases for each of the related derivative instruments, the value to the holder of the instrument generally decreases, therefore decreasing the liability on the Company’s balance sheet. Additionally, stock price volatility is one of the significant unobservable inputs used in the fair value measurement of each of the Company’s derivative instruments.

NOTE 12 - COMMITMENTS AND CONTI

NOTE 12 - COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	NOTE 12 – COMMITMENTS AND CONTINGENCIES Operating leases On April 15, 2015, the Company entered into a lease amendment agreement, whereby the Company agreed to extend the lease for office space in Los Angeles, California, commencing September 1, 2015 and expiring on August 31, 2017. In connection with the lease, the Company is obligated to lease parking spaces at an aggregate approximate cost of $978 per month. In April 2015, the Company entered into a lease for approximately 1,741 square feet of office space in Golden Valley Minnesota, whereby the Company agreed to lease premises, commencing May 1, 2015 and expiring on May 31, 2018. In connection therewith, the Company paid a security deposit of $2,712. Future minimum lease payments under these three agreements are as follows: Year Ending December 31, 2016 $ 125,192 2017 96,024 2018 13,783 $ 234,999 Rent expense charged to operations, which differs from rent paid due to rent credits and to increasing amounts of base rent, is calculated by allocating total rental payments on a straight-line basis over the term of the lease. During the years ended December 31, 2015 and 2014, rent expense was $165,514 and $77,063, respectively and as of December 31, 2015 and 2014, net deferred rent payable was $3,016 and $-0-, respectively. Included in rent expense for the year ended December 31, 2015, was temporary monthly rental expenses incurred. Employment agreements On July 14, 2014, the Company’s Board Of Directors (the “Board”) increased the size of the Board to eight members and appointed Gregory D. Cash and Patrick J. Gallagher as members of the Board, effective as of July 15, 2014, to serve for a term expiring at the Company’s 2015 annual meeting of stockholders. In addition, the Board appointed Mr. Cash to serve as the Company’s president and chief executive officer. In connection with the appointment of Mr. Cash, on July 15, 2014 (the “Effective Date”), the Company entered into an employment agreement with Mr. Cash (the “Employment Agreement”). The Employment Agreement has an initial term of three years that expires on July 15, 2017. Under the Employment Agreement, Mr. Cash is entitled to an annual base salary of $275,000. Upon the Company closing an equity or equity-linked financing with proceeds to the Company of at least $3.5 million (a “Qualified Financing”), Mr. Cash’s annual base salary will automatically increase to $325,000 and he will receive (i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date. In accordance with the Employment Agreement, on July 15, 2014, the Company granted Mr. Cash an incentive stock option to purchase 1,265,769 shares of the Company’s common stock, made pursuant to an Incentive Stock Option Agreement. The option has an exercise price of $2.21, which was the fair market value of the Company’s common stock on the date of grant, and a term that expires ten years from the date of grant. The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days. Litigation On January 7, 2014, David Drachman, the Company’s former chief executive officer and president, filed a statement of claim against the Company with the American Arbitration Association with respect to his resignation from his positions with us in November 2013. Mr. Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company. During the year ended December 31, 2014, the Company settled the above claim for $100,000 with payments over six months. As of December 31, 2015 and 2014, $13,333 and $66,667 was outstanding, respectively. The Company is subject at times to other legal proceedings and claims, which arise in the ordinary course of its business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity. There was no outstanding litigation as of December 31, 2015.

NOTE 13 - INCOME TAXES

NOTE 13 - INCOME TAXES	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	NOTE 13 – INCOME TAXES At December 31, 2015, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $11,200,000, expiring in the year 2035, that may be used to offset future taxable income. The Company has provided a valuation reserve against the full amount of the net operating loss benefit, since in the opinion of management based upon the earnings history of the Company; it is more likely than not that the benefits will not be realized. Due to possible significant changes in the Company's ownership, the future use of its existing net operating losses may be limited. All or portion of the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to fully utilize these potential tax benefits. During the year ended December 31, 2015, the Company has increased the valuation allowance from $2,300,000 to $3,700,000. We have adopted the provisions of ASC 740-10-25, which provides recognition criteria and a related measurement model for uncertain tax positions taken or expected to be taken in income tax returns. ASC 740-10-25 requires that a position taken or expected to be taken in a tax return be recognized in the financial statements when it is more likely than not that the position would be sustained upon examination by tax authorities. Tax position that meet the more likely than not threshold are then measured using a probability weighted approach recognizing the largest amount of tax benefit that is greater than 50% likely of being realized upon ultimate settlement. The Company had no tax positions relating to open income tax returns that were considered to be uncertain. The Company is required to file income tax returns in the U.S. Federal jurisdiction and in California. The Company is no longer subject to income tax examinations by tax authorities for tax years ending before December 31, 2011. The effective rate differs from the statutory rate of 34% for due to the following: 2015 2014 Statutory rate on pre-tax book loss (34.00 )% (34.00 )% Gain on change in fair value of derivatives (11.5 )% - % Stock based compensation 28.6 % 23.0 % Financing costs 2.1 % 2.4 % Valuation allowance 14.8 % 8.6 % 0.00 % 0.00 % The Company’s deferred taxes as of December 31, 2015 and 2014 consist of the following: 2015 2014 Non-Current deferred tax asset: Net operating loss carry-forwards $ 3,700,000 $ 2,300,000 Valuation allowance (3,700,000 ) (2,300,000 ) Net non-current deferred tax asset $ - $ -

NOTE 14 - SUBSEQUENT EVENTS

NOTE 14 - SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events [Text Block]	NOTE 14 – SUBSEQUENT EVENTS Common stock: On January 6, 2016, the Company issued 75,000 shares of common stock to Mr. Chaussy, the Company’s Chief Financial Officer, for the second half of his grant dated April 30, 2015 at a cost basis of $2.90 per share. On January 20, 2016, the Company issued 75,000 shares of common stock to a consultant for services pursuant to a grant dated December 7, 2015 at a cost basis of $1.31. On February 9, 2016, the Company issued Alpha Capital an aggregate of 54,859 shares of common stock in exchange for 75 shares of our Series C 9% Convertible Preferred Stock and accrued dividends. On March 11, 2016, the Company issued 25,000 shares of common stock to a consultant for services pursuant to a General Release and Non-Disparagement agreement dated March 1, 2015 at a cost basis of $1.26. October 2015 Private Placement On February 9, 2016, as part of a private placement transaction of our common stock and warrants, certain accredited investors purchased an aggregate of 50,000 shares of common stock and warrants to purchase 25,000 shares of common stock at $1.95, expiring February 9, 2019, for an aggregate purchase price of $75,000. In addition, the Company issued 6,000 warrants to purchase the Company’s common stock at $1.50, expiring February 9, 2019 for placement agent services. On March 9, 2016, as part of a private placement transaction of our common stock and warrants, certain accredited investors purchased an aggregate of 200,000 shares of common stock and warrants to purchase 100,000 shares of common stock at $1.95, expiring March 9, 2019, for an aggregate purchase price of $300,000. In addition, the Company issued 12,000 warrants to purchase the Company’s common stock at $1.50, expiring March 9, 2019 for placement agent services.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Business and organization BioSig Technologies Inc. (the “Company”) was initially incorporated on February 24, 2009 under the laws of the State of Nevada and subsequently re-incorporated in the state of Delaware in 2011. The Company and its efforts are principally devoted to improving the quality of cardiac recordings obtained during ablation of atrial fibrillation (AF) and ventricular tachycardia (VT). The Company has not generated any revenue to date and consequently its operations are subject to all risks inherent in the establishment of a new business enterprise.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company recognizes revenue in accordance with Accounting Standards Codification subtopic 605-10, Revenue Recognition (“ASC 605-10”) which requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgments regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded.
Use of Estimates, Policy [Policy Text Block]	Use of estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates include the recoverability and useful lives of long-lived assets, the fair value of the Company’s stock, stock-based compensation, fair values relating to warrant and other derivative liabilities and the valuation allowance related to deferred tax assets. Actual results may differ from these estimates.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments and related items, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents. The Company places its cash and temporary cash investments with credit quality institutions. At times, such amounts may be in excess of the FDIC insurance limit. At December 31, 2015 and 2014, deposits in excess of FDIC limits were $703,234 and $-0-, respectively.
Prepaid Expenses Policy [Policy Text Block]	Prepaid Expenses From time to time, the Company issues shares of its common stock for services to be performed. The fair value of the common stock is determined at the date of the contract for services and is amortized ratably over the term of the contract. As of December 31, 2015 and 2014, prepaid expenses relating to stock based payments were $-0- and $56,667, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives of 3 to 5 years. When retired or otherwise disposed, the related carrying value and accumulated depreciation are removed from the respective accounts and the net difference less any amount realized from disposition, is reflected in earnings.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Long-Lived Assets The Company follows Accounting Standards Codification 360-10-15-3, “Impairment or Disposal of Long-lived Assets,” which established a “primary asset” approach to determine the cash flow estimation period for a group of assets and liabilities that represents the unit of accounting for a long-lived asset to be held and used. Long-lived assets to be held and used are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. Long-lived assets to be disposed of are reported at the lower of carrying amount or fair value less cost to sell.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”) requires disclosure of the fair value of certain financial instruments. The carrying value of cash and cash equivalents, accounts payable and accrued liabilities as reflected in the balance sheets, approximate fair value because of the short-term maturity of these instruments. All other significant financial assets, financial liabilities and equity instruments of the Company are either recognized or disclosed in the financial statements together with other information relevant for making a reasonable assessment of future cash flows, interest rate risk and credit risk. Where practicable the fair values of financial assets and financial liabilities have been determined and disclosed; otherwise only available information pertinent to fair value has been disclosed. The Company follows Accounting Standards Codification subtopic 820-10, Fair Value Measurements and Disclosures (“ASC 820-10”) and Accounting Standards Codification subtopic 825-10, Financial Instruments (“ASC 825-10”), which permits entities to choose to measure many financial instruments and certain other items at fair value.
Derivatives, Policy [Policy Text Block]	Derivative Instrument Liability The Company accounts for derivative instruments in accordance with ASC 815, which establishes accounting and reporting standards for derivative instruments and hedging activities, including certain derivative instruments embedded in other financial instruments or contracts and requires recognition of all derivatives on the balance sheet at fair value, regardless of hedging relationship designation. Accounting for changes in fair value of the derivative instruments depends on whether the derivatives qualify as hedge relationships and the types of relationships designated are based on the exposures hedged. At December 31, 2015 and 2014, the Company did not have any derivative instruments that were designated as hedges. At December 31, 2015 and 2014, the Company had outstanding preferred stock and warrants that contained embedded derivatives. These embedded derivatives include certain conversion features and reset provisions. (See Note 7 and Note 8).
Research and Development Expense, Policy [Policy Text Block]	Research and development costs The Company accounts for research and development costs in accordance with the Accounting Standards Codification subtopic 730-10, Research and Development (“ASC 730-10”). Under ASC 730-10, all research and development costs must be charged to expense as incurred. Accordingly, internal research and development costs are expensed as incurred. Third-party research and developments costs are expensed when the contracted work has been performed or as milestone results have been achieved. Company-sponsored research and development costs related to both present and future products are expensed in the period incurred. The Company incurred research and development expenses of $1,238,548 and $547,996 for the year ended December 31, 2015 and 2014, respectively.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company follows Accounting Standards Codification subtopic 740-10, Income Taxes (“ASC 740-10”) for recording the provision for income taxes. Deferred tax assets and liabilities are computed based upon the difference between the financial statement and income tax basis of assets and liabilities using the enacted marginal tax rate applicable when the related asset or liability is expected to be realized or settled. Deferred income tax expenses or benefits are based on the changes in the asset or liability during each period. If available evidence suggests that it is more likely than not that some portion or all of the deferred tax assets will not be realized, a valuation allowance is required to reduce the deferred tax assets to the amount that is more likely than not to be realized. Future changes in such valuation allowance are included in the provision for deferred income taxes in the period of change. Deferred income taxes may arise from temporary differences resulting from income and expense items reported for financial accounting and tax purposes in different periods. Deferred taxes are classified as current or non-current, depending on the classification of assets and liabilities to which they relate. Deferred taxes arising from temporary differences that are not related to an asset or liability are classified as current or non-current depending on the periods in which the temporary differences are expected to reverse and are considered immaterial.
Earnings Per Share, Policy [Policy Text Block]	Net Income (loss) Per Common Share The Company computes earnings (loss) per share under Accounting Standards Codification subtopic 260-10, Earnings Per Share (“ASC 260-10”). Net loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the year. Diluted earnings per share, if presented, would include the dilution that would occur upon the exercise or conversion of all potentially dilutive securities into common stock using the “treasury stock” and/or “if converted” methods as applicable. The computation of basic and diluted loss per share as of December 31, 2015 and 2014 excludes potentially dilutive securities when their inclusion would be anti-dilutive, or if their exercise prices were greater than the average market price of the common stock during the period. Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2015 2014 Series C convertible preferred stock 980,667 1,807,333 Options to purchase common stock 7,780,190 5,990,190 Warrants to purchase common stock 7,078,685 5,113,990 Totals 15,839,542 12,911,513
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock based compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on vesting dates and interim financial reporting dates until the service period is complete. The fair value amount is then recognized over the period during which services are required to be provided in exchange for the award, usually the vesting period. Stock-based compensation expense is recorded by the Company in the same expense classifications in the statements of operations, as if such amounts were paid in cash. As of December 31, 2015, there were outstanding stock options to purchase 7,780,190 shares of common stock, 5,613,501 shares of which were vested. As of December 31, 2014, the Company had 5,990,190 options outstanding to purchase shares of common stock, of which 3,799,559 were vested.
Registration Rights Policy [Policy Text Block]	Registration Rights The Company accounts for registration rights agreements in accordance with the Accounting Standards Codification subtopic 825-20, Registration Payment Arraignments (“ASC 825-20”). Under ASC 825-20, the Company is required to disclose the nature and terms of the arraignment, the maximum potential amount and to assess each reporting period the probable liability under these arraignments and, if exists, to record or adjust the liability to current period operations. On June 23, 2014, the Company filed Form S-1/A became effective with the Securities and Exchange Commission. As such, the Company determined that payments were due under its registration rights agreement and therefore accrued $55,620 as interest expense during the year ended December 31, 2014 for the liability under the registration rights agreements. During the year ended December 31, 2015, the Company estimated the liability at $-0- and therefore recorded the change to current period operations. Beginning on October 23, 2015, the Company entered into subscription agreements with certain accredited investors pursuant to which the Company sold to the investors units , which each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock (the “ Private Placement
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Pronouncements There were various updates recently issued, most of which represented technical corrections to the accounting literature or application to specific industries and are not expected to a have a material impact on the Company’s financial position, results of operations or cash flows.

NOTE 1 - SUMMARY OF SIGNIFICA23

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows: 2015 2014 Series C convertible preferred stock 980,667 1,807,333 Options to purchase common stock 7,780,190 5,990,190 Warrants to purchase common stock 7,078,685 5,113,990 Totals 15,839,542 12,911,513

NOTE 4 - PROPERTY AND EQUIPME24

NOTE 4 - PROPERTY AND EQUIPMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment as of December 31, 2015 and 2014 is summarized as follows: 2015 2014 Computer equipment $ 68,449 $ 54,900 Furniture and fixtures 10,117 7,803 Subtotal 78,566 62,703 Less accumulated depreciation (60,158 ) (49,683 ) Property and equipment, net $ 18,408 $ 13,020

NOTE 5 - ACCOUNTS PAYABLE AND25

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2015
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Accounts payable and accrued expenses at December 31, 2015 and 2014 consist of the following: 2015 2014 Accrued accounting and legal $ 112,723 $ 190,767 Accrued reimbursements 13,613 26,792 Accrued consulting 15,200 16,334 Accrued research and development expenses 34,179 93,407 Accrued credit card obligations - 13,278 Accrued payroll - 62,068 Accrued liquidated damages - 55,620 Accrued office and other 31,482 29,093 Deferred rent 3,016 - Accrued settlement related to arbitration 13,333 66,667 $ 223,546 $ 554,026

NOTE 10 - OPTIONS AND WARRANTS

NOTE 10 - OPTIONS AND WARRANTS (Tables)	12 Months Ended
	Dec. 31, 2015
Disclosure Text Block Supplement [Abstract]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2015: Options Outstanding Options Exercisable Weighted Average Exercisable Exercise Number of Remaining Life Number of Price Options In Years Options $ 1.01-2.00 1,544,642 6.3 910,142 2.01-3.00 5,935,548 6.3 4,403,359 3.01-4.00 300,000 9.3 300,000 7,780,190 6.4 5,613,501
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity and related information for the 2012 Plan for the years ended December 31, 2015 and 2014 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2014 2,990,977 $ 2.05 6.02 $ - Grants 3,478,498 2.39 8.10 $ - Exercised - - - - Canceled (479,285 ) $ (2.00 ) - Outstanding at December 31, 2014 5,990,190 $ 2.25 6.7 $ 3,267,692 Grants 1,800,000 2.70 8.9 $ - Exercised (10,000 ) 2.09 Canceled - Outstanding at December 31, 2015 7,780,190 $ 2.30 6.4 $ - Exercisable at December 31, 2015 5,613,501 $ 2.35 5.8 $ -
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	During the years ended December 31, 2015 and 2014, the Company granted options to purchase the Company’s common stock in connection with services rendered. Vesting is as follows: 1,491,983 Exercisable immediately 125,000 Per quarter, over one year 1,126,552 Per quarter, over two years 734,963 Performance contingent 3,478,498 737,500 Exercisable immediately 155,000 Per quarter, over one year 250,000 Per quarter, over three years 225,000 One year anniversary 300,000 1/12 per month beginning first month anniversary 100,000 50% one year anniversary, 50% two year anniversary 32,500 Performance contingent 1,800,000
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	The fair value of the granted options granted was determined using the Black Scholes option pricing model with the following assumptions: Dividend yield: -0- % Volatility 119.43% to 129.88 % Risk free rate: 0.48% to 2.53 % Expected life: 7 to 10 years Estimated fair value of the Company’s common stock $ $2.21 to $2.50 Estimated forfeiture rate 0 % Dividend yield: -0- % Volatility 118.56% to 130.30 % Risk free rate: 1.19% to 2.37 % Expected life: 7 to 10 years Estimated fair value of the Company’s common stock $ 1.42 to $3.99 Estimated forfeiture rate 0 %
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock activity for the year ended December 31, 2015: Restricted shares issued as of January 1, 2015 - Granted 175,000 Total restricted shares issued as of December 31, 2015 175,000 Vested restricted shares as of December 31, 2015 (75,000 ) Unvested restricted shares as of December 31, 2015 100,000
Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Table Text Block]	The following table summarizes information with respect to outstanding warrants to purchase common stock of the Company, all of which were exercisable, at December 31, 2015: Exercise Number Expiration Price Outstanding Date $ 0.001 383,320 January 2020 $ 1.50 3,991,391 February 2018 to December 2018 $ 1.84 35,076 January 2020 $ 1.95 654,674 October 2018 to December 2018 $ 2.00 100,000 August 2018 $ 2.02 30,755 January 2020 $ 2.50 100,000 August 2018 $ 2.75 228,720 August 2019 to September 2019 $ 3.67 214,193 December 2018 to January 2019 $ 3.75 1,340,556 April 2019 to March 2020 7,078,685
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	A summary of the warrant activity for the years ended December 31, 2015 and 2014 is as follows: Weighted-Average Weighted-Average Remaining Aggregate Shares Exercise Price Contractual Term Intrinsic Value Outstanding at January 1, 2014 2,717,258 $ 2.28 6.02 - Grants 2,396,732 $ 4.64 2.05 - Exercised - - - - Canceled - - - - Outstanding at December 31, 2014 5,113,990 $ 1.71 3.6 $ 6,041,436 Grants 3,728,479 2.62 2.3 - Exercised (164,184 ) 1.58 Canceled (1,599,600 ) $ 2.50 Outstanding at December 31, 2015 7,078,685 $ 2.02 3.0 $ 497,933 Vested and expected to vest at December 31, 2015 7,078,685 $ 2.02 3.0 $ 497,933 Exercisable at December 31, 2015 6,945,353 $ 2.01 3.0 $ 497,933

NOTE 11 - FAIR VALUE MEASUREM27

NOTE 11 - FAIR VALUE MEASUREMENT (Tables)	12 Months Ended
	Dec. 31, 2015
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following table provides a summary of changes in fair value of the Company’s level 3 financial liabilities as of December 31, 2015: Warrant Liability Derivative Balance, December 31, 2014 (and prior) $ - $ - Total (gains) losses Initial fair value of derivative at March 31, 2015, reclassified from equity - 1,242,590 Initial fair value of warrant liability at March 31, 2015, reclassified from equity 4,097,444 - Initial fair value of derivative at date of issuance of Series C Preferred Stock - 250,540 Initial fair value of warrant liability at the date of issuance 334,784 - Transfers out due to conversion of Series C Preferred Stock - (639,467 ) Transfers out due to exercise of warrants (265,955 ) - Mark to market to December 31, 2015 (2,545,074 ) (568,506 ) Balance, December 31, 2015 $ 1,621,199 $ 285,157 Gain on change in warrant and derivative liabilities for the year ended December 31, 2015 $ 2,545,074 $ 568,506

NOTE 12 - COMMITMENTS AND CON28

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments under these three agreements are as follows: Year Ending December 31, 2016 $ 125,192 2017 96,024 2018 13,783 $ 234,999

NOTE 13 - INCOME TAXES (Tables)

NOTE 13 - INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2015
Income Tax Disclosure [Abstract]
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	The effective rate differs from the statutory rate of 34% for due to the following: 2015 2014 Statutory rate on pre-tax book loss (34.00 )% (34.00 )% Gain on change in fair value of derivatives (11.5 )% - % Stock based compensation 28.6 % 23.0 % Financing costs 2.1 % 2.4 % Valuation allowance 14.8 % 8.6 % 0.00 % 0.00 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred taxes as of December 31, 2015 and 2014 consist of the following: 2015 2014 Non-Current deferred tax asset: Net operating loss carry-forwards $ 3,700,000 $ 2,300,000 Valuation allowance (3,700,000 ) (2,300,000 ) Net non-current deferred tax asset $ - $ -

NOTE 1 - SUMMARY OF SIGNIFICA30

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Cash, Uninsured Amount	$ 703,234	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized	0	56,667
Research and Development Expense	$ 1,238,548	$ 547,996
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	7,780,190	5,990,190	2,990,977
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	5,613,501
Registration Payment Arrangement, Accrual Carrying Value	$ 0	$ 55,620
Employee Stock Option [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number (in Shares)	7,780,190	5,990,190
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in Shares)	5,613,501	3,799,559
Minimum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 1 - SUMMARY OF SIGNIFICA31

NOTE 1 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	15,839,542	12,911,513
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,780,190	5,990,190
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	7,078,685	5,113,990
Series C Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities	980,667	1,807,333

NOTE 2 - GOING CONCERN AND MA32

NOTE 2 - GOING CONCERN AND MANAGEMENT’S LIQUIDITY PLANS (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net Income (Loss) Available to Common Stockholders, Basic	$ (9,812,974)	$ (8,773,399)
Net Cash Provided by (Used in) Operating Activities	$ (4,523,751)	$ (1,997,072)

NOTE 3 - RELATED PARTY TRANSA33

NOTE 3 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	Nov. 18, 2015	Oct. 23, 2015	Oct. 19, 2015	May. 11, 2015	Apr. 30, 2015	Mar. 23, 2015	Mar. 05, 2015	Sep. 12, 2014	Sep. 01, 2014	Feb. 28, 2014	Jan. 31, 2014	Jan. 09, 2013	Aug. 01, 2012	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Jan. 31, 2014	Mar. 31, 2014	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Due to Related Parties, Current (in Dollars)														$ 12,716									$ 40,293				$ 12,716	$ 40,293
Stock Issued During Period, Shares, New Issues	200,000	66,667						4,000																24,490			2,645,432	956,179
Class of Warrant or Rights, Granted	100,000	33,334		374,641				2,000																12,246			3,728,479	2,396,732
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 300,000	$ 100,000						$ 10,000																$ 60,000			$ 4,759,798	$ 1,969,410
Proceeds from Related Party Debt (in Dollars)							$ 10,000
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures					150,000
Shares Issued, Price Per Share (in Dollars per share)					$ 2.90															$ 2.90			$ 2.50					$ 2.50
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)														$ 0									$ 56,667				$ 0	$ 56,667
Stock Issued During Period, Value, Other (in Dollars)																												$ 65,000
Conversion of Stock, Shares Issued														84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334	59,267
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights					One half of the shares vested immediately; the second half vests on January 1, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																											1,800,000	3,478,498
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)														$ 2.09													$ 2.09
Due to Other Related Parties, Classified, Current (in Dollars)														$ 0									$ 11,250				$ 0	$ 11,250
Series C Preferred Stock [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, New Issues				450																						2,181
Class of Warrant or Rights, Granted				374,641						3,721,518		1,330,627
Conversion of Stock, Shares Issued						169,334								84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334					1,430,871
Conversion of Stock, Shares Converted						200								100	117	170	200	350	323	180	200	50	70				1,690
Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Description of Transaction																									which resulted in Dr. Holzer agreeing to receive (i) a payment of $65,000, to be paid by us upon our closing of a capital raising transaction that results in proceeds to us of at least $5 million, and (ii) a future option grant to purchase 125,000 shares of our common stock, in exchange for acknowledging that no other payments are due by us to Dr. Holzer pursuant to the consulting agreement.
Stock Issued During Period, Shares, Issued for Services									26,000
Stock Issued During Period, Shares, New Issues											24,490
Class of Warrant or Rights, Granted											12,246
Proceeds from Issuance or Sale of Equity (in Dollars)											$ 60,000
Extinguishment of Debt, Amount (in Dollars)																												$ 87,500
Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures																												34,000
Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures (in Dollars)																												$ 85,000
Shares Issued, Price Per Share (in Dollars per share)																							$ 2.50					$ 2.50
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)																							$ 56,667					$ 56,667
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			100,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)			$ 1.56
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date			Oct. 19, 2025
Director [Member] | Settlement of Related Party Debt [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share)																							$ 2.50					$ 2.50
Stock Issued During Period, Shares, Other																												26,000
Stock Issued During Period, Value, Other (in Dollars)																												$ 65,000
Director [Member] | Share-based Compensation Award, Tranche One [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Director [Member] | Share-based Compensation Award, Tranche Two [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage			50.00%
Monthly Payments [Member] | Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction (in Dollars)													$ 10,000
Initial Payment [Member] | Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Related Party Transaction, Amounts of Transaction (in Dollars)													$ 7,500
Shares Issued for Additional Year of Consulting Services [Member] | Director [Member]
NOTE 3 - RELATED PARTY TRANSACTIONS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services									34,000

NOTE 4 - PROPERTY AND EQUIPME34

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Depreciation	$ 10,475	$ 15,809
Minimum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
NOTE 4 - PROPERTY AND EQUIPMENT (Details) [Line Items]
Property, Plant and Equipment, Useful Life	5 years

NOTE 4 - PROPERTY AND EQUIPME35

NOTE 4 - PROPERTY AND EQUIPMENT (Details) - Schedule of Property, Plant and Equipment - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 78,566	$ 62,703
Less accumulated depreciation	(60,158)	(49,683)
Property and equipment, net	18,408	13,020
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	68,449	54,900
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 10,117	$ 7,803

NOTE 5 - ACCOUNTS PAYABLE AND36

NOTE 5 - ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Details) - Schedule of Accounts Payable and Accrued Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Schedule of Accounts Payable and Accrued Liabilities [Abstract]
Accrued accounting and legal	$ 112,723	$ 190,767
Accrued reimbursements	13,613	26,792
Accrued consulting	15,200	16,334
Accrued research and development expenses	34,179	93,407
Accrued credit card obligations	0	13,278
Accrued payroll	0	62,068
Accrued liquidated damages	0	55,620
Accrued office and other	31,482	29,093
Deferred rent	3,016	0
Accrued settlement related to arbitration	13,333	66,667
	$ 223,546	$ 554,026

NOTE 6 - REDEEMABLE PREFERRED37

NOTE 6 - REDEEMABLE PREFERRED STOCK (Details) - USD ($)

Jun. 23, 2014

Nov. 28, 2011

Dec. 31, 2015

Nov. 30, 2015

Oct. 31, 2015

Jul. 31, 2015

Jun. 30, 2015

May. 31, 2015

Apr. 30, 2015

Mar. 31, 2015

Jan. 31, 2015

Dec. 31, 2014

May. 31, 2011

NOTE 6 - REDEEMABLE PREFERRED STOCK (Details) [Line Items]

Preferred Stock, Shares Authorized

1,000,000

1,000,000

Preferred Stock, Par or Stated Value Per Share

$ 0.001

$ 0.001

Conversion of Stock, Shares Issued

84,667

99,061

143,935

169,333

296,333

273,473

152,401

169,334

42,334

59,267

Series A Preferred Stock [Member]

NOTE 6 - REDEEMABLE PREFERRED STOCK (Details) [Line Items]

Preferred Stock, Shares Authorized

200

184.4

200

Preferred Stock, Liquidation Preference, Value

$ 5,000

Preferred Stock, Dividend Rate, Percentage

5.00%

Preferred Stock, Par or Stated Value Per Share

$ 5,000

Preferred Stock, Dividend Payment Terms

payable quarterly

Preferred Stock, Voting Rights

no voting rights, however without the affirmative vote of all the holders of then outstanding shares of the Series A preferred stock, the Company cannot, (a) alter or change adversely the powers, preferences or rights

Preferred Stock, Redemption Terms

The Series A preferred stock is mandatorily redeemable on December 31, 2014 (as modified) at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.

Preferred Stock, Redemption Date

Dec. 31, 2014

Preferred Stock Redemption, Percentage

14.00%

Preferred Stock, Redemption Price Per Share

$ 1.84

Conversion of Stock, Shares Issued

577,901

Conversion of Stock, Amount Converted

$ 141,331

Series B Preferred Stock [Member]

NOTE 6 - REDEEMABLE PREFERRED STOCK (Details) [Line Items]

Preferred Stock, Shares Authorized

600

600

177.5

Preferred Stock, Liquidation Preference, Value

$ 5,000

Preferred Stock, Dividend Rate, Percentage

5.00%

Preferred Stock, Par or Stated Value Per Share

$ 5,000

Preferred Stock, Dividend Payment Terms

payable quarterly

Preferred Stock, Voting Rights

no voting rights

Preferred Stock, Redemption Terms

The Series B preferred stock is mandatorily redeemable on December 31, 2014 at a price equal to the Stated Value ($5,000) plus an amount equal to all accumulated and unpaid dividends. If the Company fails to redeem at redemption, the unpaid redemption price will accrue at 14% per annum until paid.

Preferred Stock, Redemption Date

Dec. 31, 2014

Preferred Stock Redemption, Percentage

14.00%

Preferred Stock, Redemption Price Per Share

$ 2.02

Conversion of Stock, Shares Issued

493,818

Conversion of Stock, Amount Converted

$ 110,026

NOTE 7 - SERIES C 9% CONVERTI38

NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) - USD ($)	Nov. 18, 2015	Oct. 23, 2015	May. 11, 2015	Mar. 23, 2015	Sep. 12, 2014	Feb. 28, 2014	Feb. 06, 2013	Jan. 09, 2013	May. 11, 2011	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Jan. 31, 2014	Mar. 31, 2015	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2013
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Rights, Granted	100,000	33,334	374,641		2,000															12,246			3,728,479	2,396,732
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 1.50
Warrants, Term of Warrants			5 years																					5 years
Class of Warrant or Right, Outstanding										7,078,685									5,113,990				7,078,685	5,113,990	2,717,258	2,717,258
Adjustments to Additional Paid in Capital, Other (in Dollars)																								$ 87,500
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																								$ 52,800
Temporary Equity, Amortization Period																										1 year
Debt Conversion, Converted Instrument, Shares Issued																								26,000
Stock Issued During Period, Shares, New Issues	200,000	66,667			4,000															24,490			2,645,432	956,179
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)																							$ 450,000	$ 0
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)			$ 506,348							$ 285,157							$ 1,242,590		$ 0		$ 1,242,590		285,157	0
Fair Value Assumptions, Expected Dividend Rate																					0.00%
Fair Value Assumptions, Expected Volatility Rate																					141.00%
Conversion of Stock, Shares Issued										84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334	59,267
Derivative Liability, Current (in Dollars)			$ 334,784							$ 1,621,199							$ 4,097,444		$ 0		$ 4,097,444		1,621,199	0
Dividends Payable, Current (in Dollars)										340,291									445,069				340,291	$ 445,069
Registration Payment Arrangement, Term																								the Company entered into a registration rights agreement with the purchasers pursuant to which the Company agreed to provide certain registration rights with respect to the common stock issuable upon conversion of Series C Preferred Stock and exercise of the warrants issued to holders of Series C Preferred Stock. Specifically, the Company agreed to file a registration statement with the Securities and Exchange Commission covering the resale of the common stock issuable upon conversion of the Series C Preferred Stock and exercise of the warrants on or before July 22, 2013 and to cause such registration statement to be declared effective by the Securities and Exchange Commission, in the event that the registration statement is not reviewed by the Securities and Exchange Commission, within five trading days after the Company is notified that registration statement is not being reviewed by the Securities and Exchange Commission, and by November 22, 2013 in the event that the registration statement is reviewed by the Securities and Exchange Commission and the Securities and Exchange Commission issues comments.If (i) the registration statement is not filed by July 22, 2013, (ii) the registration statement is not declared effective by the Securities and Exchange Commission within five trading days after the Company is notified that the registration statement is not being reviewed by the Securities and Exchange Commission, in the case of a no review, (iii) the registration statement is not declared effective by the Securities and Exchange Commission by November 22, 2013 in the case of a review by the Securities and Exchange Commission pursuant to which the Securities and Exchange Commission issues comments or (iv) the registration statement ceases to remain continuously effective for more than 20 consecutive calendar days or more than an aggregate of 45 calendar days during any 12-month period after its first effective date, then the Company is subject to liquidated damage payments to the holders of the shares sold in the private placement in an amount equal to 0.25% of the aggregate purchase price paid by such purchasers per month of delinquency.Notwithstanding the foregoing, (i) the maximum aggregate liquidated damages due under the registration rights agreement shall be 3% of the aggregate purchase price paid by the purchasers, and (ii) if any partial amount of liquidated damages remains unpaid for more than seven days, the Company shall pay interest of 18% per annum, accruing daily, on such unpaid amount.Pursuant to the registration rights agreement, the Company must maintain the effectiveness of the registration statement from the effective date until the date on which all securities registered under the registration statement have been sold, or are otherwise able to be sold pursuant to Rule 144 without volume or manner-of-sale restrictions, subject to the right to suspend or defer the use of the registration statement in certain events.
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)										$ 0									$ 55,620				$ 0	$ 55,620
Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Shares Authorized								4,200		4,200									2,781				4,200	2,781
Preferred Stock, Dividend Rate, Percentage								9.00%
Temporary Equity, Par Value (in Dollars)								$ 1,000
Preferred Stock, Dividend Payment Terms								payable quarterly
Preferred Stock, Voting Rights								The holders of the Series C Preferred Stock vote together with the holders of our common stock on an as-converted basis, but may not vote the Series C Preferred Stock in excess of the beneficial ownership limitation of the Series C Preferred Stock. The beneficial ownership limitation is 4.99% of our then outstanding shares of common stock following such conversion or exercise, which may be increased to up to 9.99% of our then outstanding shares of common stock following such conversion or exercise upon the request of an individual holder.
Preferred Stock, Beneficial Ownership Limitation and Covenant, Description								The beneficial ownership limitation is determined on an individual holder basis, such that the as-converted number of shares of one holder is not included in the shares outstanding when calculating the limitation for a different holder. In addition, absent the approval of holders representing at least 67% of the outstanding shares of the Series C Preferred Stock, which holders must include Alpha Capital Anstalt, so long as Alpha Capital Anstalt holds not less than $100,000 of Series C Preferred Stock, we may not (i) increase the number of authorized shares of preferred stock, (ii) amend our charter documents, including the terms of the Series C Preferred Stock, in any manner adverse to the holders of the Series C Preferred Stock, including authorizing or creating any class of stock ranking senior to, or otherwise pari passu with, the shares of Series C Preferred Stock as to dividends, redemption or distribution of assets upon a liquidation, or (iii) perform certain covenants, including:● incur additional indebtedness; ● permit liens on assets; ● repay, repurchase or otherwise acquire more than a de minimis number of shares of capital stock; ● pay cash dividends to our stockholders; and ● engage in transactions with affiliates.
Convertible Preferred Stock, Terms of Conversion								Any holder of Series C Preferred Stock is entitled at any time to convert any whole or partial number of shares of Series C Preferred Stock into shares of our common stock at a price of $1.50 per share. The Series C Preferred Stock is subject to full ratchet anti-dilution price protection upon the issuance of equity or equity-linked securities at an effective common stock purchase price of less than $1.50 per share as well as other customary anti-dilution protection.In the event that(i) we fail to, or announce our intention not to, deliver common stock share certificates upon conversion of our Series C Preferred Stock prior to the seventh trading day after such shares are required to be delivered, (ii) we fail for any reason to pay in full the amount of cash due pursuant to our failure to deliver common stock share certificates upon conversion of our Series C Preferred Stock within five calendar days after notice therefor is delivered, (iii) we fail to have available a sufficient number of authorized and unreserved shares of common stock to issue upon a conversion of our Series C Preferred Stock, (iv) we fail to observe or perform any other covenant, agreement or warranty contained in, or otherwise commit any breach of our obligations under, the securities purchase agreement, the registration rights agreement, the certificate of designation or the warrants entered into pursuant to the private placement transaction for our Series C Preferred Stock, which failure or breach could have a material adverse effect, and such failure or breach is not cured within 30 calendar days after written notice was delivered, (v) we are party to a change of control transaction, (vi) we file for bankruptcy or a similar arrangement or are adjudicated insolvent, (vii) we are subject to a judgment, including an arbitration award against us, of greater than $100,000, and such judgment remains unvacated, unbonded or unstayed for a period of 45 calendar days,The holders of the Series C Preferred Stock are entitled, among other rights, to redeem their shares of Series C Preferred Stock at any time for greater than their stated value or increase the dividend rate on their shares of Series C Preferred Stock to 18%.
Temporary Equity, Redemption Price Per Share (in Dollars per share)								$ 1.50
Class of Warrant or Rights, Granted			374,641			3,721,518		1,330,627
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 1.50			$ 1.50		$ 2.61												$ 2.61
Warrants, Term of Warrants								5 years	5 years
Warrant, Description of Warrant								after six months from the issuance date, there is no effective registration statement registering the resale, or no current prospectus available for the resale, of the shares of common stock underlying the warrants, the warrants may be exercised by means of a “cashless exercise”.
Class of Warrant or Right, Outstanding																				2,138,800
Temporary Equity, Liquidation Preference (in Dollars)										$ 1,471,000									$ 2,711,000				$ 1,471,000	$ 2,711,000	$ 2,781,000	$ 2,781,000
Stock Issued During Period, Shares, New Issues			450																			2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)			$ 450,000																			$ 1,814,910
Conversion of Stock, Shares Issued				169,334						84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334					1,430,871
Conversion of Stock, Shares Converted				200						100	117	170	200	350	323	180	200	50	70				1,690
Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants (in Dollars)			$ 450,000
Temporary Equity, Shares Outstanding										1,471									2,711				1,471	2,711
Dividend Declared [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Dividends Payable, Current (in Dollars)										$ 340,291									$ 445,069				$ 340,291	$ 445,069
Options Held [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Other (in Dollars)																									1,303,671
Temporary Equity, Liquidation Preference (in Dollars)																									1,303,671	1,303,671
Warrant [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)																	$ 4,097,444				4,097,444
Derivative Liability, Current (in Dollars)										1,621,199													1,621,199
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																							$ (4,097,444)
Warrant [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Adjustments to Additional Paid in Capital, Warrant Issued (in Dollars)																									1,064,739
Temporary Equity, Liquidation Preference (in Dollars)																									1,064,739	1,064,739
Issuance Costs [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Temporary Equity, Liquidation Preference (in Dollars)																									$ 412,590	$ 412,590
Full-Ratchet Anti-Dilution Protection Provision [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 1.50
Class of Warrant or Right, Outstanding								2,315,301
Embedded Derivative Financial Instruments [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)																	$ 1,242,590				$ 1,242,590
Fair Value Assumptions, Expected Term			2 years																				2 years
Fair Value Assumptions, Risk Free Interest Rate			0.25%																				1.01%
Fair Value Assumptions, Expected Dividend Rate			0.00%																		0.00%		0.00%
Fair Value Assumptions, Expected Volatility Rate			140.00%																		141.00%		147.00%
Derivative Liability, Current (in Dollars)										$ 285,157													$ 285,157
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																							$ (1,242,590)
Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term										2 years
Fair Value Assumptions, Expected Dividend Rate																							0.00%
Conversion of Stock, Shares Converted																		50
Embedded Derivative, No Longer Bifurcated, Amount Reclassified to Stockholders' Equity (in Dollars)																							$ 639,467
Bridge Loan [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Debt Conversion, Converted Instrument, Shares Issued							600
Minimum [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																					2 years 284 days
Fair Value Assumptions, Risk Free Interest Rate																					0.56%
Minimum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																					0.56%
Minimum [Member] | Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																							0.23%
Fair Value Assumptions, Expected Volatility Rate																							139.00%
Maximum [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Expected Term																					3 years 6 months
Fair Value Assumptions, Risk Free Interest Rate																					0.89%
Maximum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																					0.89%
Maximum [Member] | Embedded Derivative Financial Instruments [Member] | Series C Preferred Stock [Member]
NOTE 7 - SERIES C 9% CONVERTIBLE PREFERRED STOCK (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate																							0.27%
Fair Value Assumptions, Expected Volatility Rate																							147.00%

NOTE 8 - WARRANT AND DERIVATI39

NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) - USD ($)	May. 11, 2015	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)	$ 506,348	$ 1,242,590	$ 285,157	$ 0
Derivative Liability, Current (in Dollars)	$ 334,784	$ 4,097,444	1,621,199	0
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value Assumptions, Expected Volatility Rate		141.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			3,113,580	$ 0
Embedded Derivative Financial Instruments [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)		$ 1,242,590
Derivative Liability, Current (in Dollars)			$ 285,157
Fair Value Assumptions, Risk Free Interest Rate	0.25%		1.01%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Fair Value Assumptions, Expected Volatility Rate	140.00%	141.00%	147.00%
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 568,506
Fair Value Assumptions, Expected Term	2 years		2 years
Warrant [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Embedded Derivative, Fair Value of Embedded Derivative Liability (in Dollars)		$ 4,097,444
Derivative Liability, Current (in Dollars)			$ 1,621,199
Derivative, Gain (Loss) on Derivative, Net (in Dollars)			$ 2,545,074
Minimum [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.56%
Fair Value Assumptions, Expected Term		2 years 284 days
Minimum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.56%
Maximum [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.89%
Fair Value Assumptions, Expected Term		3 years 6 months
Maximum [Member] | Embedded Derivative Financial Instruments [Member]
NOTE 8 - WARRANT AND DERIVATIVE LIABILITIES (Details) [Line Items]
Fair Value Assumptions, Risk Free Interest Rate		0.89%

NOTE 9 - STOCKHOLDER EQUITY (De

NOTE 9 - STOCKHOLDER EQUITY (Details) - USD ($)	Nov. 18, 2015	Oct. 23, 2015	May. 11, 2015	May. 08, 2015	May. 05, 2015	Apr. 15, 2015	Mar. 23, 2015	Sep. 12, 2014	Jun. 23, 2014	Feb. 28, 2014	Jan. 31, 2014	Jan. 09, 2013	May. 11, 2011	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Jan. 31, 2014	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Oct. 19, 2015	Nov. 28, 2011	May. 31, 2011
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized														1,000,000									1,000,000			1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)														$ 0.001									$ 0.001			$ 0.001	$ 0.001
Conversion of Stock, Shares Issued														84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334	59,267
Stock Issued During Period, Shares, New Issues	200,000	66,667						4,000																24,490		2,645,432	956,179
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)																										$ 450,000	$ 0
Class of Warrant or Rights, Granted	100,000	33,334	374,641					2,000																12,246		3,728,479	2,396,732
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 1.50
Warrants, Term of Warrants			5 years																								5 years
Stock Issued During Period, Value, New Issues (in Dollars)																										$ 4,759,798	$ 1,969,410
Common Stock, Shares Authorized														50,000,000									50,000,000			50,000,000	50,000,000
Common Stock, Par or Stated Value Per Share (in Dollars per share)														$ 0.001									$ 0.001			$ 0.001	$ 0.001
Common Stock, Shares, Issued														16,825,703									11,179,266			16,825,703	11,179,266
Common Stock, Shares, Outstanding														16,825,703									11,179,266			16,825,703	11,179,266
Stock Issued During Period, Shares, Share-based Compensation, Gross																											654,000
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)																											$ 1,635,000
Debt Conversion, Converted Instrument, Shares Issued																											26,000
Debt Conversion, Original Debt, Amount (in Dollars)																											$ 65,000
Shares Issued, Price Per Share (in Dollars per share)																				$ 2.90			$ 2.50				$ 2.50
Proceeds from Issuance or Sale of Equity (in Dollars)	$ 300,000	$ 100,000						$ 10,000																$ 60,000		$ 4,759,798	$ 1,969,410
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																										10,000	0
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)														$ 2.09												$ 2.09
Class of Warrant or Rights, Exercised																										164,184	0
Payments of Stock Issuance Costs (in Dollars)																										$ 608,356
Private Placement, Unit Description		each unit consisting of one share of the Company’s common stock and a warrant to purchase one half of one share of common stock
Registration Rights Agreement, Description		The registration rights agreements require the Company to file a registration statement within 45 calendar days upon close of the private placement and to be effective 120 calendar days thereafter. As of the date of filing, the Private Placement has not closed
Registration Payment Arrangement, Accrual Carrying Value (in Dollars)														$ 0									$ 55,620			0	$ 55,620
Deferred Compensation Liability, Current (in Dollars)														$ 0									$ 226,305			$ 0	$ 226,305
Exercise of Warrants for Cash [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)				$ 2.50	$ 3.67									$ 3.09												$ 3.09
Stock Issued During Period, Shares, Conversion of Convertible Securities				4,000	4,082																					8,082
Class of Warrant or Rights, Exercised				4,000	4,082
Cashless Exercise of Warrants [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities						99,552																				99,552
Class of Warrant or Rights, Exercised						156,102																				156,102
2012 Equity Incentive Plan [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross																										1,452,500
Stock Issued During Period, Value, Share-based Compensation, Gross (in Dollars)																										$ 3,341,752
Shares Issued, Price Per Share (in Dollars per share)														$ 2.30												$ 2.30
Series A Preferred Stock [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized														200									184.4			200	184.4			200
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																														$ 5,000
Conversion of Stock, Shares Issued									577,901
Series B Preferred Stock [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized														600									177.5			600	177.5		600
Preferred Stock, Par or Stated Value Per Share (in Dollars per share)																													$ 5,000
Conversion of Stock, Shares Issued									493,818
Series C Preferred Stock [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Preferred Stock, Shares Authorized														4,200									4,200			4,200	4,200
Temporary Equity, Shares Authorized												4,200		4,200									2,781			4,200	2,781
Conversion of Stock, Shares Issued							169,334							84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334				1,430,871
Conversion of Stock, Shares Converted							200							100	117	170	200	350	323	180	200	50	70			1,690
Stock Issued During Period, Shares, New Issues			450																						2,181
Proceeds from Issuance of Redeemable Preferred Stock (in Dollars)			$ 450,000																						$ 1,814,910
Class of Warrant or Rights, Granted			374,641							3,721,518		1,330,627
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)			$ 1.50							$ 1.50	$ 2.61	$ 2.61												$ 2.61
Warrants, Term of Warrants												5 years	5 years
Stock Issued During Period, Value, New Issues (in Dollars)																										$ 2,146,302
Temporary Equity, Shares Issued														1,471									2,711			1,471	2,711
Temporary Equity, Shares Outstanding														1,471									2,711			1,471	2,711
Director [Member]
NOTE 9 - STOCKHOLDER EQUITY (Details) [Line Items]
Stock Issued During Period, Shares, New Issues											24,490
Class of Warrant or Rights, Granted											12,246
Shares Issued, Price Per Share (in Dollars per share)																							$ 2.50				$ 2.50
Proceeds from Issuance or Sale of Equity (in Dollars)											$ 60,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)																												$ 1.56
Deferred Compensation Liability, Current (in Dollars)																							$ 226,305				$ 226,305

NOTE 10 - OPTIONS AND WARRANT41

NOTE 10 - OPTIONS AND WARRANTS (Details) - USD ($)	Dec. 22, 2015	Dec. 18, 2015	Nov. 18, 2015	Oct. 29, 2015	Oct. 23, 2015	Aug. 17, 2015	May. 11, 2015	May. 08, 2015	May. 05, 2015	Apr. 22, 2015	Apr. 15, 2015	Mar. 31, 2015	Feb. 27, 2015	Feb. 10, 2015	Jan. 23, 2015	Sep. 12, 2014	Feb. 28, 2014	Jan. 31, 2014	Jan. 09, 2013	Oct. 19, 2012	May. 11, 2011	Dec. 31, 2014	Sep. 30, 2014	Aug. 31, 2014	Apr. 30, 2014	Jan. 31, 2014	Mar. 31, 2015	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																													1,800,000	3,478,498
Share Based Compensation Award, Options Granted in Period, Term of Awards																														7 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period																													10,000	0
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)																													$ 2.09
Share-based Compensation (in Dollars)																													$ 7,968,036	$ 5,743,425
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)																						$ 56,667							$ 0	$ 56,667
Class of Warrant or Rights, Granted			100,000		33,334		374,641									2,000										12,246			3,728,479	2,396,732
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$ 1.50
Warrants, Term of Warrants							5 years																							5 years
Class of Warrant or Right, Outstanding																						5,113,990							7,078,685	5,113,990	2,717,258
Class of Warrant or Rights, Exercised																													164,184	0
Fair Value Assumptions, Expected Volatility Rate																											141.00%
Fair Value Assumptions, Expected Dividend Rate																											0.00%
Stock Issued During Period, Shares, New Issues			200,000		66,667											4,000										24,490			2,645,432	956,179
Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)																													$ 1.30
Class of Warrant or Rights, Granted	166,667	116,668	188,335	43,334	108,336													64,626				358,470	93,600	135,120	137,856
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.95	$ 1.95	$ 1.95	$ 1.95														$ 3.67					$ 2.75	$ 2.75	$ 3.75	$ 3.67
Warrants, Term of Warrants																		5 years					5 years	5 years	5 years
Warrant, Expriation Date	Dec. 22, 2018	Dec. 18, 2018	Nov. 18, 2018	Oct. 29, 2018	Oct. 23, 2018
Stock Issued During Period, Shares, New Issues					1.95
Warrants at $2.50 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																													$ 2.50
Class of Warrant or Right, Outstanding																													100,000
Warrants at $2.50 [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted												410,360	223,000		428,400							204,840
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)												$ 2.50	$ 2.50		$ 2.50							$ 2.50					$ 2.50			$ 2.50
Warrants, Term of Warrants																						6 months
Warrant, Expriation Date												Jul. 31, 2015	Jul. 31, 2015	Jul. 31, 2015	Jul. 31, 2015
Warrants at $3.75 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																													$ 3.75
Class of Warrant or Right, Outstanding																													1,340,556
Warrants at $3.75 [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted												307,770			321,300							153,630
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)												$ 3.75	$ 3.75	$ 3.75	$ 3.75							$ 3.75					$ 3.75			$ 3.75
Warrant, Expriation Date												Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2020	Mar. 31, 2020							Mar. 31, 2020
Warrants at $2.00 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)																													$ 2
Class of Warrant or Right, Outstanding																													100,000
Series C Preferred Stock [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted							374,641										3,721,518		1,330,627
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$ 1.50										$ 1.50	$ 2.61	$ 2.61							$ 2.61
Warrants, Term of Warrants																			5 years		5 years
Class of Warrant or Right, Outstanding																		2,138,800								2,138,800
Stock Issued During Period, Shares, New Issues							450																					2,181
Series C Preferred Stock [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted							374,641
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)							$ 1.50
Warrant, Expriation Date							May 11, 2020
Series C Preferred Stock [Member] | Warrants at $2.50 [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted														337,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)														$ 2.50
Series C Preferred Stock [Member] | Warrants at $3.75 [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted													167,250	252,750
Restricted Stock [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted																													175,000
Share-based Compensation (in Dollars)																													$ 338,614	$ 0
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized (in Dollars)																													$ 53,386
Cashless Exercise of Warrants [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Stock Issued During Period, Shares, Conversion of Convertible Securities											99,552																		99,552
Class of Warrant or Rights, Exercised											156,102																		156,102
Exercise of Warrants for Cash [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 2.50	$ 3.67																				$ 3.09
Stock Issued During Period, Shares, Conversion of Convertible Securities								4,000	4,082																				8,082
Class of Warrant or Rights, Exercised								4,000	4,082
Services Provided [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)																													$ 46,993
Warrants, Term of Warrants						1 month
Warrant, Expriation Date						Aug. 17, 2018
Class of Warrant or Rights, Vesting Rights						vest at 1/12 per month over one year
Warrants, Fair Value of Warrants, Granted (in Dollars)						$ 104,505
Fair Value Assumptions, Expected Dividend Rate						0.00%
Services Provided [Member] | Warrants at $2.50 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted						100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 2.50
Services Provided [Member] | Warrants at $2.00 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted						100,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)						$ 2
Private Placmeent Services [Member] | Private Placement [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Class of Warrant or Rights, Granted	20,000	20,000	25,200	6,134	11,334
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)	$ 1.50	$ 1.50	$ 1.50	$ 1.50	$ 1.50
Warrant, Expriation Date	Dec. 22, 2018	Dec. 18, 2018	Nov. 18, 2018	Oct. 29, 2018	Oct. 23, 2018
2012 Equity Incentive Plan [Member] | Officers, Directors and Key Consultants [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																													1,800,000	3,478,498
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted																													1,452,500	654,000
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Lower Range Limit (in Dollars per share)																													$ 1.56	$ 2.21
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range, Upper Range Limit (in Dollars per share)																													$ 3.99	$ 2.50
Share Based Compensation Award, Options Granted in Period, Term of Awards																													7 years
2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized																				11,686,123
Share-based Compensation Arrangement by Share-based Payment Award, Terms of Award																				the exercise price of an Incentive Stock Option should not be less than 110% of fair value of the common stock at the date of the grant for a 10% or more stockholder and 100% of fair value for a grantee who is not 10% stockholder.
Common Stock, Capital Shares Reserved for Future Issuance																				1,250,000
Share Price (in Dollars per share)																													$ 1.30
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period										10,000
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share)										$ 2.09
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value (in Dollars)																													$ 4,471,603	$ 4,193,425
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options (in Dollars)																						$ 3,778,589							$ 1,782,575	$ 3,778,589
Maximum [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)																						$ 2.50							$ 3.99	$ 2.50
Fair Value Assumptions, Risk Free Interest Rate																											0.89%
Maximum [Member] | Services Provided [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)						$ 1.40
Fair Value Assumptions, Expected Volatility Rate						118.88%
Fair Value Assumptions, Risk Free Interest Rate						1.31%
Maximum [Member] | 2012 Equity Incentive Plan [Member] | Employee Stock Option [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																				10 years
Minimum [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)																						$ 2.21							$ 1.42	$ 2.21
Fair Value Assumptions, Risk Free Interest Rate																											0.56%
Minimum [Member] | Services Provided [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) [Line Items]
Share Price (in Dollars per share)						$ 1
Fair Value Assumptions, Expected Volatility Rate						118.80%
Fair Value Assumptions, Risk Free Interest Rate						0.92%

NOTE 10 - OPTIONS AND WARRANT42

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Number of Options	7,780,190	5,990,190	2,990,977
Options Outstanding, Weighted Average Remaining Life	6 years 146 days	6 years 255 days	6 years 7 days
Options Exercisable, Number of Options	5,613,501
Options at $1.01-$2.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 1.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 2
Options Outstanding, Number of Options	1,544,642
Options Outstanding, Weighted Average Remaining Life	6 years 109 days
Options Exercisable, Number of Options	910,142
Options at $2.01-$3.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 2.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 3
Options Outstanding, Number of Options	5,935,548
Options Outstanding, Weighted Average Remaining Life	6 years 109 days
Options Exercisable, Number of Options	4,403,359
Options at $3.01-$4.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in Dollars per share)	$ 3.01
Options Outstanding, Exercise Price, Upper Range Limit (in Dollars per share)	$ 4
Options Outstanding, Number of Options	300,000
Options Outstanding, Weighted Average Remaining Life	9 years 109 days
Options Exercisable, Number of Options	300,000

NOTE 10 - OPTIONS AND WARRANT43

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation, Stock Options, Activity - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Share-based Compensation, Stock Options, Activity [Abstract]
Options Outstanding, Shares	7,780,190	5,990,190	2,990,977
Options Outstanding, Weighted-Average Exercise Price	$ 2.30	$ 2.25	$ 2.05
Options Outstanding, Weighted-Average Remaining Contractual Term	6 years 146 days	6 years 255 days	6 years 7 days
Options Outstanding, Aggregate Intrinsic Value	$ 0	$ 3,267,692	$ 0
Exercisable at December 31, 2015	5,613,501
Exercisable at December 31, 2015	$ 2.35
Exercisable at December 31, 2015	5 years 292 days
Exercisable at December 31, 2015	$ 0
Options Granted, Shares	1,800,000	3,478,498
Options Granted, Weighted-Average Exercise Price	$ 2.70	$ 2.39
Options Granted, Weighted-Average Remaining Contractual Term	8 years 328 days	8 years 36 days
Options Exercised, Shares	(10,000)	0
Options Exercised, Weighted-Average Exercise Price	$ 2.09	$ 0
Options Canceled, Shares	0	(479,285)
Options Canceled, Weighted-Average Exercise Price	$ 0	$ (2)

NOTE 10 - OPTIONS AND WARRANT44

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	1,800,000	3,478,498
Exercisable Immediately [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	737,500	1,491,983
Per Quarter, Over One Year [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	155,000	125,000
Per Quarter, Over Two Years [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	250,000	1,126,552
Performance Contingent [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	32,500	734,963
One Year Anniversary [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	225,000
Share-based Compensation Award, Tranche Four [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	300,000
50% One Year Anniversary, 50% Two Year Anniversary [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Line Items]
Number of Options Granted	100,000

NOTE 10 - OPTIONS AND WARRANT45

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Dividend yield:	0.00%	0.00%
Estimated forfeiture rate	0.00%	0.00%
Minimum [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	118.56%	119.43%
Risk free rate:	1.19%	0.48%
Expected life:	7 years	7 years
Estimated fair value of the Company’s common stock (in Dollars per share)	$ 1.42	$ 2.21
Maximum [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]
Volatility	130.30%	129.88%
Risk free rate:	2.37%	2.53%
Expected life:	10 years	10 years
Estimated fair value of the Company’s common stock (in Dollars per share)	$ 3.99	$ 2.50

NOTE 10 - OPTIONS AND WARRANT46

NOTE 10 - OPTIONS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity - Restricted Stock [Member]	12 Months Ended
	Dec. 31, 2015shares
NOTE 10 - OPTIONS AND WARRANTS (Details) - Nonvested Restricted Stock Shares Activity [Line Items]
Restricted shares issued as of January 1, 2015	0
Granted	175,000
Total restricted shares issued as of December 31, 2015	175,000
Vested restricted shares as of December 31, 2015	(75,000)
Unvested restricted shares as of December 31, 2015	100,000

NOTE 10 - OPTIONS AND WARRANT47

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range - $ / shares	12 Months Ended
	Dec. 31, 2015	May. 11, 2015	Dec. 31, 2014	Dec. 31, 2013
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)		$ 1.50
Number of Warrants Outstanding	7,078,685		5,113,990	2,717,258
Warrants at $0.001 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 0.001
Number of Warrants Outstanding	383,320
Expiration Date, Warrants	January 2,020
Warrants at $1.50 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.50
Number of Warrants Outstanding	3,991,391
Expiration Date, Warrants	February 2018 to December 2018
Warrants at $1.84 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.84
Number of Warrants Outstanding	35,076
Expiration Date, Warrants	January 2,020
Warrants at $1.95 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 1.95
Number of Warrants Outstanding	654,674
Expiration Date, Warrants	October 2018 to December 2018
Warrants at $2.00 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.02 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.02
Number of Warrants Outstanding	30,755
Expiration Date, Warrants	January 2,020
Warrants at $2.50 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.50
Number of Warrants Outstanding	100,000
Expiration Date, Warrants	August 2,018
Warrants at $2.75 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 2.75
Number of Warrants Outstanding	228,720
Expiration Date, Warrants	August 2019 to September 2019
Warrants at $3.67 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.67
Number of Warrants Outstanding	214,193
Expiration Date, Warrants	December 2018 to January 2019
Warrants at $3.75 [Member]
NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Warrants or Rights, Shares Authorized, by Exercise Price Range [Line Items]
Exercise Price, Warrants (in Dollars per share)	$ 3.75
Number of Warrants Outstanding	1,340,556
Expiration Date, Warrants	April 2019 to March 2020

NOTE 10 - OPTIONS AND WARRANT48

NOTE 10 - OPTIONS AND WARRANTS (Details) - Schedule of Stockholders' Equity Note, Warrants or Rights - USD ($)	Nov. 18, 2015	Oct. 23, 2015	May. 11, 2015	Sep. 12, 2014	Jan. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Schedule of Stockholders' Equity Note, Warrants or Rights [Abstract]
Warrants Outstanding, Shares						7,078,685	5,113,990	2,717,258
Warrants Outstanding, Weighted-Average Exercise Price						$ 2.02	$ 1.71	$ 2.28
Warrants Outstanding, Weighted-Average Remaining Contractual Term						3 years	3 years 219 days	6 years 7 days
Warrants Outstanding, Aggregate Intrinsic Value						$ 497,933	$ 6,041,436
Vested and expected to vest at December 31, 2015						7,078,685
Vested and expected to vest at December 31, 2015						$ 2.02
Vested and expected to vest at December 31, 2015						3 years
Vested and expected to vest at December 31, 2015						$ 497,933
Exercisable at December 31, 2015						6,945,353
Exercisable at December 31, 2015						$ 2.01
Exercisable at December 31, 2015						3 years
Exercisable at December 31, 2015						$ 497,933
Warrants Granted, Shares	100,000	33,334	374,641	2,000	12,246	3,728,479	2,396,732
Warrants Granted, Weighted-Average Exercise Price						$ 2.62	$ 4.64
Warrants Granted, Weighted-Average Remaining Contractual Term						2 years 109 days	2 years 18 days
Warrants Exercised, Shares						(164,184)	0
Warrants Exercised, Weighted-Average Exercise Price						$ 1.58	$ 0
Warrants Canceled, Shares						(1,599,600)	0
Warrants Canceled, Weighted-Average Exercise Price						$ 2.50	$ 0

NOTE 11 - FAIR VALUE MEASUREM49

NOTE 11 - FAIR VALUE MEASUREMENT (Details) - USD ($)	Dec. 31, 2015	May. 11, 2015	Mar. 31, 2015	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Embedded Derivative, Fair Value of Embedded Derivative Liability	$ 285,157	$ 506,348	$ 1,242,590	$ 0
Derivative Liability, Current	$ 1,621,199	$ 334,784	$ 4,097,444	$ 0

NOTE 11 - FAIR VALUE MEASUREM50

NOTE 11 - FAIR VALUE MEASUREMENT (Details) - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Total (gains) losses
Gain on change in warrant and derivative liabilities for the year ended December 31, 2015	$ 3,113,580	$ 0
Embedded Derivative Financial Instruments [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014 (and prior)	0
Total (gains) losses
Initial fair value of derivative reclassified from equity	1,242,590
Initial fair value	250,540
Transfers out	(639,467)
Mark to market to December 31, 2015	(568,506)
Balance, December 31, 2015	285,157	0
Gain on change in warrant and derivative liabilities for the year ended December 31, 2015	568,506
Warrant [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance, December 31, 2014 (and prior)	0
Total (gains) losses
Initial fair value of derivative reclassified from equity	4,097,444
Initial fair value	334,784
Transfers out	(265,955)
Mark to market to December 31, 2015	(2,545,074)
Balance, December 31, 2015	1,621,199	$ 0
Gain on change in warrant and derivative liabilities for the year ended December 31, 2015	$ 2,545,074

NOTE 12 - COMMITMENTS AND CON51

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details)	Apr. 30, 2015ft²	Apr. 15, 2015USD ($)	Jul. 15, 2014USD ($)$ / sharesshares	Jan. 07, 2014	Apr. 30, 2015USD ($)ft²	Dec. 31, 2015USD ($)$ / sharesshares	Dec. 31, 2014USD ($)shares
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Operating Leases, Rent Expense | $						$ 165,514	$ 77,063
Deferred Rent Credit, Current | $						$ 3,016	$ 0
Number of Directors			8
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares						1,800,000	3,478,498
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares						$ 2.09
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights	One half of the shares vested immediately; the second half vests on January 1, 2016
Settlement Liabilities, Current | $						$ 13,333	$ 66,667
Chief Executive Officer [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Deferred Compensation Arrangement with Individual, Requisite Service Period			3 years
Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitments, Description			(i) a one-time payment equal to the difference between the amount he would have earned if his base salary was $325,000 and the amount he actually earned at his base salary of $275,000 for the time period from the Effective Date until the closing of such Qualified Financing and (ii) a one-time cash bonus of $30,000. If the Company does not complete a Qualified Financing within six months after the Effective Date, Mr. Cash’s annual base salary will nonetheless increase to $325,000 and he will receive the same one-time payment unless the Company reasonably determines that the failure to complete such Qualified Financing was within the reasonable control of Mr. Cash. Mr. Cash is also eligible to receive an annual bonus equal to at least 50% of the sum of his base salary and one-time payment, based on the achievement of reasonable performance criteria to be determined by the Board in consultation with Mr. Cash within 90 days of the Effective Date.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares			1,265,769
Share-based Compensation Arrangement by Share-basd Payment Award, Options, Exercise Price (in Dollars per share) | $ / shares			$ 2.21
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period			10 years
Chief Executive Officer [Member] | Employee Agreement [Member] | Signing Bonus [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment | $			$ 30,000
Building [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Lease Expiration Date		Aug. 31, 2017			May 31, 2018
Operating Leases, Rent Expense, Minimum Rentals | $		$ 978			$ 2,712
Area of Real Estate Property (in Square Feet) | ft²	1,741				1,741
Litigation with Former Chief Executive Officer [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Loss Contingency, Damages Sought				Mr. Drachman alleges, among other things, that (i) the Company misled him with respect to the status of our technology and required him to perform capital raising duties that had not been previously agreed upon, (ii) he resigned from his positions with us for good reason, as such term was defined in his employment agreement with the Company, and (iii) he, in his individual capacity, has full rights to the ownership and control of a patent application describing a combined ablation and recording unit directed at the use of electrocardiography sensing for control of radiofrequency renal denervation that we filed with the U.S. Patent and Trademark Office during the time Mr. Drachman served in his positions with the Company.
Loss Contingency, Settlement Agreement, Terms							Company settled the above claim for $100,000 with payments over six months
Litigation Settlement, Amount | $							$ 100,000
Settlement Liabilities, Current | $						$ 13,333	$ 66,667
Share-based Compensation Award, Tranche One [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number (in Shares) | shares			542,473
Share-based Compensation Award, Tranche One [Member] | Options Vesting in Eleven Equal Installments [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights			The option will vest as follows (i) 542,473 shares of common stock will vest in eleven equal installments of 45,206 shares of common stock and one final installment of 45,207 shares of common stock on a quarterly basis with the first installment vesting on the Effective Date and subsequent installments vesting every three months thereafter; (ii) 180,824 shares of common stock will vest immediately upon completion of a Qualified Financing; (iii) 180,824 shares of common stock will vest upon the listing of the Company’s common stock on a recognized U.S. national securities exchange (i.e., NYSE, MKT LLC, The Nasdaq Stock Market LLC or the New York Stock Exchange); (iv) 180,824 shares of common stock will vest upon the 510(k) clearance or any other type of clearance deemed necessary by the U.S. Food and Drug Administration of the Company’s PURE (Precise Uninterrupted Real-time evaluations of Electrograms) EP technology platform; and (v) 180,824 shares of common stock will vest upon the Company achieving a market capitalization of $150,000,000 and maintaining such market capitalization for at least 90 consecutive calendar days.
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			45,206
Share-based Compensation Award, Tranche One [Member] | Final Installment of Vested Options [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			45,207
Share-based Compensation Award, Tranche Two [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			180,824
Share-based Compensation Award, Tranche Three [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			180,824
Share-based Compensation Award, Tranche Four [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | shares						300,000
Share-based Compensation Award, Tranche Four [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			180,824
Share-based Compensation Award, Tranche Five [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares (in Shares) | shares			180,824
Minimum [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Qualified Financing Amount | $			$ 3,500,000
Minimum [Member] | Chief Executive Officer [Member] | Employee Agreement [Member] | Annual Salary [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment | $			275,000
Maximum [Member] | Chief Executive Officer [Member] | Employee Agreement [Member]
NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) [Line Items]
Other Commitment | $			$ 325,000

NOTE 12 - COMMITMENTS AND CON52

NOTE 12 - COMMITMENTS AND CONTINGENCIES (Details) - Schedule of Future Minimum Rental Payments for Operating Leases	Dec. 31, 2015USD ($)
Schedule of Future Minimum Rental Payments for Operating Leases [Abstract]
2,016	$ 125,192
2,017	96,024
2,018	13,783
	$ 234,999

NOTE 13 - INCOME TAXES (Details

NOTE 13 - INCOME TAXES (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 11,200,000
Operating Loss Carryforwards, Expiration Date 1	2,035
Deferred Tax Assets, Valuation Allowance	$ 3,700,000	$ 2,300,000
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%	34.00%

NOTE 13 - INCOME TAXES (Detail

NOTE 13 - INCOME TAXES (Details) - Schedule of Effective Income Tax Rate Reconciliation	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Schedule of Effective Income Tax Rate Reconciliation [Abstract]
Statutory rate on pre-tax book loss	(34.00%)	(34.00%)
Gain on change in fair value of derivatives	(11.50%)	0.00%
Stock based compensation	28.60%	23.00%
Financing costs	2.10%	2.40%
Valuation allowance	14.80%	8.60%
	0.00%	0.00%

NOTE 13 - INCOME TAXES (Deta55

NOTE 13 - INCOME TAXES (Details) - Schedule of Deferred Tax Assets and Liabilities - USD ($)	Dec. 31, 2015	Dec. 31, 2014
Non-Current deferred tax asset:
Net operating loss carry-forwards	$ 3,700,000	$ 2,300,000
Valuation allowance	(3,700,000)	(2,300,000)
Net non-current deferred tax asset	$ 0	$ 0

NOTE 14 - SUBSEQUENT EVENTS (De

NOTE 14 - SUBSEQUENT EVENTS (Details) - USD ($)	Mar. 11, 2016	Mar. 09, 2016	Feb. 09, 2016	Jan. 20, 2016	Jan. 06, 2016	Nov. 18, 2015	Oct. 23, 2015	May. 11, 2015	Mar. 23, 2015	Sep. 12, 2014	Feb. 28, 2014	Jan. 09, 2013	Dec. 31, 2015	Nov. 30, 2015	Oct. 31, 2015	Jul. 31, 2015	Jun. 30, 2015	May. 31, 2015	Apr. 30, 2015	Mar. 31, 2015	Jan. 31, 2015	Dec. 31, 2014	Jan. 31, 2014	Jul. 31, 2013	Dec. 31, 2015	Dec. 31, 2014
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross																										654,000
Shares Issued, Price Per Share (in Dollars per share)																			$ 2.90			$ 2.50				$ 2.50
Conversion of Stock, Shares Issued													84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334	59,267
Stock Issued During Period, Shares, New Issues						200,000	66,667			4,000													24,490		2,645,432	956,179
Class of Warrant or Rights, Granted						100,000	33,334	374,641		2,000													12,246		3,728,479	2,396,732
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 1.50
Proceeds from Issuance or Sale of Equity (in Dollars)						$ 300,000	$ 100,000			$ 10,000													$ 60,000		$ 4,759,798	$ 1,969,410
Series C Preferred Stock [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Issued									169,334				84,667	99,061	143,935	169,333	296,333	273,473	152,401	169,334	42,334				1,430,871
Conversion of Stock, Shares Converted									200				100	117	170	200	350	323	180	200	50	70			1,690
Stock Issued During Period, Shares, New Issues								450																2,181
Class of Warrant or Rights, Granted								374,641			3,721,518	1,330,627
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)								$ 1.50			$ 1.50	$ 2.61											$ 2.61
Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Share-based Compensation, Gross					75,000
Shares Issued, Price Per Share (in Dollars per share)	$ 1.26			$ 1.31	$ 2.90
Stock Issued During Period, Shares, Issued for Services	25,000			75,000
Conversion of Stock, Shares Issued			54,859
Stock Issued During Period, Shares, New Issues		200,000	50,000
Class of Warrant or Rights, Granted		100,000	25,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.95	$ 1.95
Warrant, Expriation Date		Mar. 9, 2019	Feb. 9, 2019
Proceeds from Issuance or Sale of Equity (in Dollars)		$ 300,000	$ 75,000
Subsequent Event [Member] | Series C Preferred Stock [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Conversion of Stock, Shares Converted			75
Warrants Issued to Placement Agents [Member] | Subsequent Event [Member]
NOTE 14 - SUBSEQUENT EVENTS (Details) [Line Items]
Class of Warrant or Rights, Granted		12,000	6,000
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per share)		$ 1.50	$ 1.50
Warrant, Expriation Date		Mar. 9, 2019	Feb. 9, 2019